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Abstract 
The proper development, differentiation and plasticity of the nervous system require an 
accurate regulation at multiple levels of gene expression. One important class of post-
transcriptional regulators are microRNAs (miRNAs), tiny RNA molecules that inhibit 
protein synthesis of target mRNAs at the level of mRNA translation and stability. 
MiRNAs have well documented roles in the control of neuronal development and 
function. Specific miRNAs, such as miR-134, regulate the local dynamic translation of 
mRNAs at the synapse thereby controlling activity-dependent changes in synaptic 
strength. MiRNAs regulate mRNA translation within a large RNA-protein complex, the 
microRNA-induced silencing complex (miRISC). Whereas the core components of 
miRISC, e.g. Argonaute (Ago) and GW182 proteins, are highly conserved, cell-type 
specific auxiliary proteins play important roles in the modulation of miRISC activity. The 
molecular mechanisms by which miRISC activity is specifically regulated in the neuronal 
system by such auxiliary proteins however are poorly described.  
This project presents the validation and evaluation of the first large scale screening study 
that was performed in order to find novel RNA-binding proteins (RBPs) that regulate 
miRISC activity in primary neurons. The RNAi-based screen identified the RBPs Nova1, 
Ncoa3 and Ewsr1 as new modulators of miRISC in neurons and further confirmed the 
function of two previously reported miRISC interacting proteins (Ddx6, Tnrc6c). 
Subsequently, Nova1 was chosen for follow-up experiments directed at the elucidation 
of the underlying molecular mechanisms. Using luciferase reporter assays for targets of 
multiple neuronal miRNAs in addition to miR-134, I obtained evidence that Nova1 
regulates miRNA activity in neurons in a general manner. In addition, I found that Nova1 
can act as a regulator of miRNA activity irrespective of the 3‘UTR context. Further data 
demonstrated that Nova1 interacts with Ago and the miR-134 target mRNA Limk1. 
Investigations on the functional relevance of this mechanism revealed that Nova1 is 
required for miR-134 mediated spine size reduction. Furthermore, I could show that 
Nova1 is necessary for the upregulation of Limk1 translation upon treatment with brain-
derived neurotrophic factor (BDNF), suggesting that Nova1 could be involved in the 
stimulus-dependent control of neuronal mRNAs. In summary, Nova1 was identified as a 
new modulator of miRISC activity in neurons and the underlying mechanism was 
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characterized in detail. The data obtained during the thesis project suggests that Nova1 is 
involved in the dynamic activity-dependent regulation of miRNA function in neurons. 
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Zusammenfassung 
Die korrekte Entwicklung, Differenzierung und Plastizität des Nervensystems erfordern 
eine genaue Regulation auf multiplen Ebenen der Genexpression.  Eine wichtige Klasse 
post-transkriptioneller Regulatoren sind mikroRNAs (miRNAs), winzige RNA-Mole-
küle, welche die Proteinsynthese von Ziel-mRNAs auf der Ebene der mRNA-Translation 
und -Stabilität inhibieren. MiRNAs haben wichtige Aufgaben in der Kontrolle der 
neuronalen Entwicklung und Funktion. Spezifische miRNAs, wie z. Bsp. miR-134, 
regulieren die lokale dynamische Translation von mRNAs an der Synapse, wodurch sie 
aktivitätsabhängige Veränderungen der Synapsenstärke kontrollieren. MiRNAs 
regulieren die mRNA Translation innerhalb eines großen RNA-Protein-Komplexes, des 
mikroRNA-induzierten Silencing Komplexes (miRISC). Während die Kernkomponenten 
des miRISC, wie z Bsp. Argonaute (Ago) und GW182 Proteine, hoch konserviert sind, 
kommen Zelltyp-spezifischen Proteinen wichtige Aufgaben in der Modulation der 
miRISC-Aktivität zu. Die molekularen Mechanismen, durch welche die miRISC-
Aktivität speziell im neuronalen System durch solche zusätzlichen Proteine reguliert 
wird, sind nur unzulänglich beschrieben. 
Dieses Projekt stellt die Validierung und Evaluierung der ersten umfangreichen 
Screening-Studie dar, die durchgeführt wurde, um neue RNA-bindende Proteine (RBP) 
zu identifizieren, welche die miRISC-Aktivität in primären Neuronen regulieren. Der 
RNAi-basierte Screen identifizierte die RBPs Nova1, Ncoa3 und Ewsr1 als neue 
Modulatoren von miRISC in Neuronen und bestätigte außerdem zwei zuvor beschriebene 
miRISC-interagierende Proteine (Ddx6, Tnrc6c). Anschließend wurde Nova1 für 
nachfolgende Experimente ausgewählt, welche zur Aufklärung der zugrundeliegenden 
Mechanismen beitrugen. Durch die Anwendung von Luciferase-Reporter Assays für Ziel-
mRNAs von multiplen neuronalen miRNAs neben miR-134 erbrachte ich Nachweise, 
dass Nova1 die miRNA-Aktivität in Neuronen auf generelle Weise reguliert. Zusätzlich 
fand ich heraus, dass Nova1 als Regulator der miRNA-Aktivität in Unabhängigkeit des 
3’UTR Kontextes agieren kann. Weitere Daten zeigen eine direkte Interaktion von Nova1 
mit der RISC Kernkomponente Ago und eine Assoziation mit der miR-134 Ziel-mRNA 
Limk1. Untersuchungen über die funktionale Bedeutung dieses Mechanismus zeigten, 
dass Nova1 für die miR-134-vermittelte Reduzierung der Größe von dendritischen 
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Dornfortsätzen notwendig ist. Außerdem wurde gezeigt, dass Nova1 für die 
hochregulierte Translation der Limk1 mRNA nach BDNF-Behandlung notwendig ist. 
Dies lässt auf eine Mitwirkung von Nova1 in der Stimulus-abhängigen Kontrolle von 
neuronalen mRNAs schließen. Zusammenfassend wurde Nova1 als neuer Modulator der 
miRISC-Aktivität in Neuronen beschrieben und die zugrundeliegenden Mechanismen 
genauer charakterisiert. Die während dieser Doktorarbeit erhaltenen Daten deuten 
zusammengenommen auf eine Beteiligung von Nova1 in der dynamischen 
aktivitätsabhängigen Regulation der miRNA-Funktion in Neuronen hin. 
   INTRODUCTION 
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1  Introduction 
1.1  Definition of microRNAs 
MicroRNAs (miRNAs) are highly conserved short RNA molecules (~22 nucleotides) that 
constitute an important class of small non-coding RNAs. As essential regulators of post-
transcriptional gene expression miRNAs are involved in a wide range of complex cellular 
processes including those that occur during development, differentiation and the 
adaptation to environmental changes. Since their first discovery in the nematode 
Caenorhabditis elegans, more than 3000 distinct miRNAs have been described in a 
variety of organisms ranging from simple eukaryotes to mammals. Nevertheless, the 
physiological role of many miRNAs is still unknown (Lee et al. 2001; Griffiths-Jones et 
al. 2008; Friedländer et al. 2014).  
1.2  Mechanisms of miRNA-mediated gene silencing  
MiRNAs are encoded within the genome as independent genes or in intronic regions of 
protein coding genes. The generation of most mammalian miRNAs is executed by the 
canonical miRNA pathway (Figure 1) that is described in the following chapter (reviewed 
by O'Carroll and Schaefer. 2013; Ha and Kim. 2014). The miRNA-mediated silencing of 
target mRNAs is enabled by a protein effector complex called the miRNA-induced 
silencing complex (miRISC) that is composed of core components and several associated 
factors.  
1.2.1  MiRNA biogenesis pathway 
MiRNA coding genes are first transcribed in the nucleus by RNA polymerase II into 
primary miRNA transcripts (pri-miRNAs) which may be several kilobases (kb) long (Lee 
et al. 2004). These transcripts fold into imperfectly paired, double stranded stem loop 
structures that are recognized in the nucleus by a specific processing complex. This so 
called microprocessor complex is composed of two core enzymes, the type III 
ribonuclease Drosha and the RNA binding protein Dgcr8 (DiGeorge syndrome critical 
region 8) and additional auxiliary subunits (Gregory et al. 2004). Dgcr8 acts as a 
   INTRODUCTION 
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molecular anchor that binds to the pri-miRNA hairpin structure and recruits Drosha by a 
direct interaction (Han et al. 2006). Drosha itself cleaves the hairpin of the pri-miRNA 
and thereby generates a shorter molecule (~ 65 nucleotides) that is called the precursor 
miRNA (pre-miR). Subsequently, the pre-miR is exported to the cytoplasm by Exportin-
5 in a GTP-dependent manner (Yi et al. 2003). In the cytoplasm, the loop region of the 
pre-miR is removed by the type III ribonuclease Dicer and its cofactor TRBP (trans-
activation response RNA-binding protein) thereby releasing an about 22 nucleotide long 
double-stranded RNA (Chendrimada et al. 2005). The small RNA duplex is then loaded 
onto an Ago protein to form an effector ribonucleoprotein, known as the miRNA-induced 
silencing complex (miRISC). However, only one strand of the duplex (mature miRNA) 
serves as a guide for the recognition of the target mRNA. 
 
 
Figure 1: Overview of the canonical miRNA biogenesis pathway (Pfaff and Meister. 2013) 
MiRNA genes are transcribed into primary miRNA transcripts. In the nucleus, the primary transcripts are 
processed by the Drosha/DGCR8 microprocessor complex to miRNA precursors. Upon export to the 
cytoplasm, the miRNA precursors are further processed by Dicer/TRBP to short double-stranded RNA. 
One strand is incorporated with Ago in the context of the miRNA-induced silencing complex (miRISC). 
MiRISC either directly cleaves target mRNAs or enables translational repression and decay of target 
mRNAs. N, nucleus; C, cytoplasm; Pol, RNA polymerase; DGCR8, DiGeorge syndrome critical region 8; 
TRBP, trans-activation response RNA-binding protein 
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The detailed mechanisms of strand selection and miRISC loading in mammals are not 
fully understood. Recent studies revealed that first the double-stranded miRNA is loaded 
onto an Ago protein that is associated with Dicer and TRBP to form the minimal RISC -
loading complex (RLC) (MacRae et al. 2008; Noland et al. 2011). Upon unwinding of 
the duplex RNA the passenger strand (miRNA* sequence) is released and degraded. The 
mature miRNA is now incorporated in the mature miRISC that enables the silencing of 
target mRNAs. 
1.2.2  MicroRNA-induced silencing complex (miRISC) 
MiRNA-mediated silencing of target mRNAs is facilitated by the miRISC that is 
composed of two core proteins and additional factors that influence miRISC activity. The 
two core factors of miRISC which are indispensable for miRNA-dependent silencing are 
(i) one member of the Ago protein family and (ii) the direct Ago interaction partner 
GW182 (glycine-tryptophan protein of 182 kDa) (reviewed by Fabian and Sonenberg, 
2012; Pfaff and Meister, 2013).  
The mammalian genome encodes four different Ago family members (Ago1-Ago4) that 
are all capable of binding miRNAs. In contrast to Ago proteins from other species, human 
Ago proteins generally appear to lack preference for specific miRNA sequences. (Czech 
et al. 2011; Burroughs et al. 2011; Dueck et al. 2012). MiRNAs loaded in Ago guide the 
miRISC to specific target mRNAs in order to initiate translational repression and mRNA 
destabilization. Generally, miRNAs bind partially complementary to target mRNAs with 
mismatches at the 3’ region but complementarity at the seed region (position 2 to 8) of 
the miRNA binding site (Bartel. 2009). In the rare case of a complete complementary 
base-pairing, exclusively Ago2 is able to catalyse endonucleolytic cleavage of the 
respective target mRNAs (Meister et al. 2004). 
The Ago protein structure is composed of the N-terminal domain, the PAZ domain, the 
middle (MID) domain and the PIWI domain. The N-terminal domain is required for 
miRNA loading and supports the unwinding of the RNA duplex (Kwak et al. 2012). The 
PAZ domain is binding to the 3’ end of the miRNA whereas the MID domain confers 
binding to the 5’end of the miRNA (Jinek et al. 2009). The PIWI domain structure is 
similar to that of the endonuclease RNase H and enables the cleavage of target mRNAs 
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at a specific nucleotide position (Song et al. 2004). Moreover, the PIWI domain functions 
as a binding platform for GW182 protein (Till et al. 2007).  
GW182 itself serves as a binding platform for additional effector proteins which in turn 
induce translational repression, deadenylation and/or degradation of target mRNAs. 
Mammalian genomes encode three GW182 paralogues which are termed TNRC6 
(trinucleotide repeat-containing protein 6) A, B and C (Eulalio et al. 2009). The N-
terminal part of the human GW182 contains a multitude of GW repeats that enable the 
direct interaction with Ago. The middle part of GW182 protein is composed of a putative 
ubiquitin-associated (UBA) domain and a glutamine (Q)-rich domain that is responsible 
for localizing GW182 to processing (P)-bodies in the cytoplasm. A silencing domain 
within the C-terminal part that is comprised of the motifs PAM2 (poly(A)-binding protein 
interacting motif 2) and RRM (RNA recognition motif) facilitates interaction of GW182 
with the deadenylation machinery. One of the direct interaction partners of GW182 is the 
poly(A)-binding protein (PABP) that is bound through the PAM2 domain. Thereby 
GW182 might interfere with translational initiation of target mRNAs by preventing the 
binding of PABP to the eukaryotic initiation factor 4G (eIF4G). Furthermore, GW182 
recruits the two cytoplasmic deadenylase complexes CCR4-NOT and PAN2-PAN3, 
promoting deadenylation of target mRNAs (Fabian et al. 2012; Huntzinger et al. 2013). 
The deadenylation of mRNAs subsequently leads to the removal of the cap structure at 
the 5’-end by decapping that gives rise to exonucleolytic degradation by the 5’-3’-
exonuclease XRN1 (Rehwinkel. 2005; Nishihara et al. 2013) (Figure 2).  
The timing and relative importance of both translational repression and mRNA 
destabilization is still under debate. Recent literature points towards a direct connection 
between both mechanisms. It is furthermore reported that translational repression occurs 
first and is then followed by deadenylation and decay of mRNAs (Béthune et al. 2012; 
Meijer et al. 2013; Huntzinger et al. 2013). On the contrary, another model suggests 
mRNA destabilization as the dominant effect of miRNAs (Eichhorn et al. 2014). 
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Figure 2: Mechanisms of miRNA-mediated gene silencing (Pfaff and Meister. 2013) 
By binding to Ago proteins miRNAs guide the miRISC to target mRNAs. Ago recruits GW182 proteins to 
initiate translational repression and mRNA decay. GW182 forms a binding platform for PABPC1 and the 
deadenylase complexes PAN2/3 and CCR4/NOT thereby inducing deadenylation of target mRNAs. 
Subsequently, the mRNA is decapped by DCP1/2 enzyme activity and degraded by the 5’-3’ exonuclease 
XRN1. 
1.3  MiRNAs in the nervous system 
The ability of miRNAs to control cellular processes by regulating gene expression is 
exceedingly important for the molecular networks that regulate the complexity of the 
nervous system. Numerous miRNAs are exclusively expressed or enriched in the brain 
and were found to be abundant in certain brain areas like the hippocampus (Bak et al. 
2008). Neuronal miRNAs exert different roles in neurogenesis, differentiation, 
maturation, physiological brain function and dysfunction (reviewed by Saba et al. 2010; 
Olde Loohuis et al. 2012).  
1.3.1  Role of miRNAs in neuronal development 
Numerous studies in different model organism revealed an important contribution of 
miRNAs to multiple stages of neuronal development by employing loss-of-function 
mutants of miRNA biogenesis pathway components resulting in a global loss of mature 
miRNAs (reviewed by Meza-Sosa et al. 2014). Early studies in zebrafish demonstrated 
that the disruption of Dicer leads to abnormal cell morphogenesis in the brain 
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development. This phenotype could be rescued by introducing miR-430 suggesting an 
essential role of this miRNA in neuronal development (Giraldez et al. 2005). Another 
important study revealed that selective ablation of Dicer in the neocortex during mouse 
embryonic development results in decreased growth of the postnatal cortex and an 
impairment in neuronal layering (Pietri Tonelli et al. 2008). Furthermore, knockout of 
Dgcr8, caused morphological abnormalities in the central nervous system and 
impairments in the dendritic arborization in mice (Stark et al. 2008). More recent work 
studied the function of individual miRNAs in the developing brain. Thereby, miR-124 
and miR-9 emerged as highly conserved brain-specific miRNAs that display important 
functions in neuronal development and differentiation of different organisms (Makeyev 
et al. 2007; Cheng et al. 2009; Coolen et al. 2013). In the developing brain miRNAs were 
also implicated in pathways that are required for processes involved in neuronal network 
formation, such as axon guidance (reviewed by Iyer et al. 2014). 
1.3.2  Role of miRNAs in mature neurons 
The main features of mature neurons are their complex structure, the connectivity 
between each other through synaptic contacts and the plasticity of these connections, by 
which neurons can adjust to changes in neuronal activity. A main research focus was on 
the function of miRNAs in synaptic plasticity, a cellular correlate of memory storage. 
Long-lasting forms of synaptic plasticity, such as long-term potentiation (LTP) or long-
term depression (LTD), involve the formation/elimination of synapses and the 
strengthening/weakening of pre-existing synapses. Such structural modifications often 
happen at the level of dendritic spines, membranous protrusions from dendrites where 
most excitatory synapses are formed. One mechanism that is important for activity-
dependent spine modifications is the local translation of specific dendritically localized 
mRNAs. Recent work established a critical function for dendritically localized miRNAs 
in the regulation of local mRNA translation and spine plasticity. Here, I will focus on 
three extensively studied miRNAs, miR-132, -134 and -138 (Bicker et al. 2014) (Figure 
3). 
miR-134 
MiR-134 is the first miRNA that was shown to localize to dendrites. MiR-134 is required 
for multiple processes that involve dendrite remodeling, including the regulation of 
dendritic spine morphogenesis and activity-dependent dendritogenesis. In addition to 
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mature miR-134, pre-miR-134 was shown to localize to dendrites, suggesting a regulatory 
function of localized pre-miR processing. Transport of pre-miR-134 to dendrites is 
dependent on the RNA helicase DHX36, which interacts with the pre-miR-134 loop 
structure (Bicker et al. 2013). MiR-134 negatively regulates the size of dendritic spines 
by repressing the translation of Limk1 mRNA. It was shown in hippocampal neurons that 
overexpression of miR-134 leads to a spine size reduction, whereas miR-134 inhibition 
increased spine size (Schratt et al. 2006). Furthermore, miR-134 regulates 
dendritogenesis by targeting the mRNA of the RNA-binding protein Pumilio2 (PUM2) 
(Fiore et al. 2009). Thus, both overexpression and inhibition of miR-134 block activity-
dependent dendritogenesis, suggesting that regulation of miR-134 levels within a narrow 
window is critical for proper neural development. Recently, the mRNA of Ubiquitin-
protein ligase E3A 1 (Ube3a1) was found as a target of several miRNAs encoded by the 
miR-379/410 cluster, including miR-134 (Valluy et al. 2015). 
miR-132 
MiR-132 belongs to the miR-212/132 family formed by four highly related miRNAs 
(miR-132 5p/3p, miR-212 5p/3p) which are highly conserved in the vertebrate lineage. 
MiR-132 promotes activity-dependent dendritogenesis and spine growth by inhibiting the 
expression of the Rho GTPase activating protein p250GAP, an upstream  inhibitor of the 
Rac-PAK signaling pathway that regulates remodeling of the actin cytoskeleton 
(Wayman et al. 2008; Siegel et al. 2009; Impey et al. 2010). Dendritic miR-132 function 
might rely on an interaction with the RNA-binding protein FMRP, which also associates 
with miRISC (Edbauer et al. 2010). Recently, miR-132-mediated translational repression 
of the matrix metalloproteinase-9 (MMP-9) mRNA was shown to be involved in activity-
dependent regulation of dendritic spine morphology (Jasińska et al. 2015). Another 
important target mRNA of miR-132 is methyl CpG-binding protein 2 (MeCP2) mRNA. 
MeCP2 is a transcriptional repressor that inhibits among other genes the expression of 
the neurotrophin BDNF. Since BDNF in turn activates miR-132, this constitutes a 
feedback control mechanism that might be involved in neuronal homeostasis (Klein et al. 
2007; Su et al. 2015).  
miR-138 
MiR-138 is another dendritic miRNA that was identified as a regulator of spine 
morphogenesis. It inhibits spine growth by repressing Lypla1 mRNA translation. The 
   INTRODUCTION 
16 
 
LYPLA1 gene encodes Apt1 (acyl-protein thioesterase 1),  a protein with depalmitoylase 
enzymatic activity (Siegel et al. 2009). The miR-138-mediated downregulation of APT1 
increases palmitoylation and therefore membrane association of the RhoA signaling 
activator Gα12/13. The resulting activation of RhoA modifies the actin cytoskeleton in 
dendritic spines which leads to spine shrinkage. Another study demonstrated that miR-
138 is associated with Lypla1 mRNA at synapses where it locally mediates its 
translational repression. Moreover, activity-regulated proteasomal degradation of 
MOV10, a component of miRISC, enables the release of Lypla1 mRNA from miR-138-
mediated translational inhibition (Banerjee et al. 2009). In addition, miR-138 expression 
was shown to correlate with short-term recognition memory in mice (Tatro et al. 2013) 
and later with memory performance in humans (Schröder et al. 2014). Intriguingly, 
mature miR-138 derives from two individual precursor forms that are encoded by two 
different genetic loci. The precursors pre-miR-138-1 and -2 exhibit differences in size, 
nucleotide sequence of the stem loop and transcription. The longer and highly expressed 
pre-miR-138-2 is thought to be the main source of mature miR-138 in the nervous system 
(Obernosterer et al. 2006). 
 
 
Figure 3: Control of dendritic spine size by miRNA regulatory pathways (Schratt. 2009) 
Dendritic spine modifications arise from dynamic changes of the actin cytoskeleton which is controlled by 
two signaling pathways, the Rho/ROCK cascade and the Rac-Limk1 cascade. Several dendritic miRNAs 
display distinct roles in the regulation of these pathways. MiR-138 mediates the repression of the 
depalmitoylation enzyme acyl-protein thioesterase 1 (APT1) thereby increasing the membrane association 
of the RhoA signaling activator Gα12/13 leading to actomyosin contraction and subsequently reduction of 
spine size. MiR-134 also induces spine shrinkage by repressing the expression of Limk1 which leads to a 
blockage of actomyosin polymerization. In contrast, miR-132 promotes spine growth by repressing the 
Rac-inactivating protein p250RhoGAP that results in actomyosin polymerization. 
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1.3.3  Role of miRNAs in neuronal diseases 
The increasing knowledge about the function of neuronal miRNAs also inspired research 
into possible roles of miRNAs in brain dysfunction. Cognitive impairments and learning 
disabilities are common characteristics of diseases of the nervous system such as Fragile 
X syndrome, Alzheimer disease, Parkinson’s disease, Huntington disease, schizophrenia, 
epilepsy and autism spectrum disorders. Several studies suggest that miRNA-mediated 
impairments in posttranscriptional regulation are causally involved in the development of 
these diseases (Saba et al. 2010; Nowak et al. 2013; Alsharafi et al. 2015). Altered 
miRNA expression in post mortem brains of patients as well as in animal models of 
neuronal diseases further support this notion (Abu-Elneel et al. 2008; Moreau et al. 2011).  
The X-chromosomally inherited neurodevelopmental disorder fragile X syndrome (FXS) 
was first associated with miRNAs (Jin et al. 2004a). Mutations in the FMR1 gene result 
in the loss of the RNA-binding protein FMRP (fragile X mental retardation protein) that 
is involved in mRNA transport and acts as a translational repressor through association 
with the miRISC. Loss of FMRP leads to increased translation of mRNAs at the synapse 
and as a consequence might cause impairments of synaptic plasticity. It was demonstrated 
that FMR1-knockout mice display an increase in dendritic spine length and density 
(Nimchinsky et al. 2001). Moreover, a FMRP knockdown study in mouse brain 
implicated FMRP in the regulation of dendritic spine morphology through an association 
with miR-125b and miR-132 (Edbauer et al. 2010).  
The dysregulation of individual miRNAs has also strongly been implicated in 
neuropsychiatric disorders such as schizophrenia and epilepsy. A high risk for developing 
schizophrenia-like symptoms is associated with microdeletions in the chromosomal 
region 22q11.2 that contains the gene encoding for the miRNA processing factor DGCR8. 
Deletions of this region are accompanied by alterations in brain miRNA biogenesis, thus 
providing a link between impaired miRNA expression and the etiology of schizophrenia 
(Stark et al. 2008). Moreover, the expression of numerous miRNAs was altered in post 
mortem brain samples of schizophrenia patients (reviewed by Beveridge et al. 2012). 
From these, miR-137 emerged as one of the most significant schizophrenia-associated 
miRNAs (Yin et al. 2014). In addition, multiple studies have linked alterations of miRNA 
expression to epilepsy (reviewed by Alsharafi et al. 2015). For example, expression levels 
of miR-132, miR-34a and miR-124 were found to be changed in experimental models of 
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induced epileptic seizures and in human epilepsy (Nudelman et al. 2010; Sano et al. 2012; 
Peng et al. 2013; Santarelli et al. 2011). Of note, miR-134 was found to be functionally 
relevant in the development of epilepsy because silencing of miR-134 prevents recurrent 
seizure occurrence in mice (Jimenez-Mateos et al. 2012) 
1.4  Regulation of neuronal miRNAs 
Since miRNAs are key regulators of activity-dependent processes in the nervous system, 
their turnover and function have to be precisely regulated, particularly in response to 
developmental or environmental cues. A particular quality of neuronal miRNAs is the 
activity-dependent regulation that enables cellular adaptation to changes in neuronal 
activity, for example during synaptic plasticity.  
1.4.1  Activity-dependent regulation of neuronal miRNAs  
Neuronal miRNAs are subject to distinct activity-dependent control mechanisms that 
operate at multiple levels, including transcription, pri-miR-processing, miRISC 
remodeling, miRNA turnover and function (Krol et al. 2010b; Treiber et al. 2012; Aksoy-
Aksel et al. 2014). The various regulatory mechanisms of the miRNA pathway are either 
accomplished by post-translational modifications of protein core components of the 
miRNA pathway or RNA-binding proteins. The latter can either have enhancing or 
decreasing modulatory effects on miRNA function (reviewed by Loffreda et al. 2015). 
Activity-dependent regulatory processes were described for several individual miRNAs 
at the synapse.  
For example, miR-132 was shown to be increased by different treatments that enhance 
neuronal activity, such as BDNF-, KCL- or bicuculline-stimulation of neurons in vitro 
(Vo et al. 2005; Wayman et al. 2008) or pilocarpine-induced seizures in rodents in vivo 
(Nudelman et al. 2010). The BDNF-mediated induction of the miR-212/132 locus occurs 
through activation of ERK1/2-signaling at the transcriptional level via two cAMP 
response elements (CRE) within the promoter region which are bound by the transcription 
factor CREB (CRE-binding protein) (Remenyi et al. 2010). Recently, miR-132 
expression was found to be induced more physiologically in response to learning and 
memory formation in mice (Hansen et al. 2013). 
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The miR-134 containing cluster miR-379-410 is another example of an activity-
dependent miRNA gene locus. The expression of miR-379-410 is induced upon neuronal 
stimulation with BDNF or KCl via activation of the transcription factor Mef2 (myocyte 
enhancer factor 2) that is associated with an upstream located regulatory element (Schratt 
et al. 2006; Fiore et al. 2009). Interestingly, the repressive activity of miR-134 within 
dendritic spines can be reversed by the activation of local BDNF signalling, possibly 
through activation of the mTOR pathway (Figure 4). This provided the first example of a 
local mechanism that controls miRNA function at the level of dendritic spines (Schratt et 
al. 2006). However, the underlying mechanisms are yet unknown. 
 
Figure 4: BDNF-induced relief of miR-134-mediated Limk1 repression (adapted from Fiore et al. 
2008) 
Within dendrites, the local Limk1 mRNA translation is repressed by active miR-134 which leads to an 
inhibition of spine growth. Upon extracellular stimulation with the neurotrophin BDNF, the miR-134-
mediated repression is relieved and Limk1 translation is induced resulting in spine growth. BDNF release 
possibly induces the activation of the mTOR pathway that could lead to miRISC inactivation by protein 
phosphorylation.  
Furthermore, there are indications that activity-dependent regulation also occurs at the 
level of pre-miR-processing. A recent study showed that neuronal stimulation with N-
Methyl-D-aspartate (NMDA) which activates NDMA receptors changes the miRNA 
expression profile in cultured hippocampal neurons and also expression levels of the 
microprocessor components DGCR8 and Drosha (Kye et al. 2011). Another study linked 
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pre-miRNA processing to changes in neuronal activity. It was found that in response to 
neuronal activity inactive Dicer is partially cleaved in a calpain-dependent manner. This 
in turn results in an increased RNAse III activity of Dicer at postsynaptic densities (Lugli 
et al. 2005). In addition, recent work demonstrated that BDNF stimulation promotes 
Dicer stabilization via phosphorylation of the cofactor TRBP (Huang et al. 2012).  
A study in retina neurons revealed that miRNA levels were dynamically increased or 
decreased in response to light and dark conditions, respectively (Krol et al. 2010a). A fast 
turnover of miRNAs was also observed in non-retinal cultured neurons, but not in non-
neuronal cells. It was further shown that inhibition of neuronal action potentials by 
tetrodotoxin (TTX) blocks the rapid turnover of miRNAs and that glutamate receptor 
stimulation induces miRNA decay. This suggests that the high turnover rate of neuronal 
miRNAs is determined by neuronal activity (Krol et al. 2010a). The molecular 
mechanisms underlying the regulation of activity-dependent miRNA turnover are still not 
known.  
1.4.2  MiRNA regulation at the level of miRISC 
The function of miRISC is regulated via modification of the core components, Ago and 
GW182, as well as via additional proteins that either positively or negatively modulate 
miRISC activity. Many miRISC-interacting proteins that enhance miRNA function 
belong to the family of DExD/H helicases, as for example Ddx6/RCK/p54 and 
MOV10/Armitage. RNA helicases support miRISC activity by RNA unwinding that can 
facilitate the incorporation of miRNAs into the miRISC as well as the interaction of 
miRNAs with their target mRNAs. Especially, the DEAD-box RNA helicase DDX6 is an 
essential miRISC component that was shown to directly interact with Ago2 thereby 
promoting miRNA-mediated translational repression (Chu et al. 2006). Moreover, Ddx6 
was reported to affect miRNA-mediated silencing of target mRNAs by direct interaction 
with the CCR4-NOT1 deadenlyase complex (Rouya et al. 2014). 
MOV10/Armitage represents an important example of activity-dependent modification 
of miRISC components. The drosophila protein Armitage as well as the human homolog 
MOV10 (Moloney leukemia virus 10) are localized to the synapse and degraded in an 
activity-dependent manner by NMDA receptor stimulation. Loss of Armitage/ MOV10 
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stimulates the translation of synaptic mRNAs, such as Limk1 and Lypla1 (Ashraf et al. 
2006; Banerjee et al. 2009).  
Other RNA-binding proteins that facilitate miRNA-mediated repression are for example 
FMRP and PUF proteins. FMRP was first shown to associate with miRISC in Drosophila 
(Caudy et al. 2002). A later study demonstrated that FMRP cooperates with distinct 
miRNAs in the silencing of synaptic mRNAs in the mouse brain (Edbauer et al. 2010). 
Moreover, FMRP is involved in a mechanism that regulates mRNA translation at 
synapses in response to receptor activation. FMRP phosphorylation promotes the 
formation of an AGO2-miR-125a inhibitory complex on PSD-95 mRNA. Upon mGluR 
signaling the repressive activity of miR-125a can be relieved by dephosphorylation of 
FMRP. This leads to a release of AGO2 from the PSD-95 mRNA and a concomitant 
increase in PSD-95 translation (Muddashetty et al. 2011). The FMRP phosphorylation 
status also regulates the repressive activity of miR-196a, however in this case it does not 
affect the association between FMRP and the miR-196a target mRNA. Furthermore, 
FMRP directly interacts with AGO2 via a specific binding pocket within the Ago2 MID 
domain (Li et al. 2014). A recent study suggested a cooperative association between 
FMRP and MOV10. It was shown that FMRP directly interacts with MOV10 in an RNA-
dependent manner and facilitates the association of MOV10 with RNAs in mouse brain 
(Kenny et al. 2014). 
Similar to FMRP the PUF proteins (e.g. Pum1/2 in mammals) enhance the miRNA 
repressive function. PUF binding motifs were found to be enriched in target mRNAs 
around miRNA binding sites suggesting an association between PUF and the miRNA 
regulatory system (Galgano et al. 2008). The ubiquitously expressed human Pumilio 
homolog 1 (PUM1) protein was shown to be phosphorylated after growth factor 
stimulation and to subsequently modulate the secondary structure of miRNA target 
mRNAs. Thereby, PUM1 promotes the accessibility of miRNA seed sequences in the 
3’UTR of target mRNAs (Kedde et al. 2010). A later study with PUF proteins from 
nematode and humans revealed a function in the repression of mRNA translation in 
cooperation with Ago. Thereby, PUF forms a complex with Ago proteins and a core 
translation elongation factor, eEF1A, which leads to attenuation of translational 
elongation of target mRNAs (Friend et al. 2012). 
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RBPs that negatively regulate miRISC function have also been reported, for example 
Dnd1 and HuR. Dnd1 relieves miRNA repression in human germline cells by blocking 
miRNA interaction with the 3’UTR of target mRNAs (Kedde et al. 2007; Kedde et al. 
2010). HuR associates with the 3’UTR of mRNAs close to the miRNA binding site and 
promotes the dissociation of miRISC from the target mRNA (Kim et al. 2009; Kundu et 
al. 2012). 
In addition, several other proteins (e.g. Rbm4, Smd1) were shown to be involved in the 
modulation of miRISC activity besides there originally described function in other 
cellular processes that are not related to miRNAs (Lin et al. 2009; Xiong et al. 2015).  
1.5  Aim of the study 
RNA-binding proteins (RBPs) that are not core components of miRISC have been shown 
to modify miRNA activity in non-neuronal cells (Fabian et al. 2012). However, miRNA 
modulating functions of RBPs in neurons are poorly described. This study aimed to 
identify new modulators of miRNA activity in neurons. Previously, our laboratory 
investigated the role of RBPs on miRNA activity in neurons using a large-scale RNAi-
based screen in primary neuron cultures (Gabriele Siegel, PhD thesis, 2011). In my PhD 
thesis it was the goal to validate a subset of the positive candidates obtained from the 
initial screen. Next, I aimed to choose one positive candidate of the secondary screen for 
a detailed characterization of its potential regulatory role in miRNA function. In this 
regard, I intended to analyze a putative involvement in the miRNA-mediated inhibition 
of target mRNAs. In addition, I planned to examine the molecular mechanisms underlying 
the function of this candidate with respect to a potential association with miRISC.  
Finally, I aimed to investigate whether this RBP is involved in the activity-dependent 
regulation of miRNA function in neurons.
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2 Materials and Methods 
2.1  Materials 
2.1.1  Chemicals and reagents 
Agarose        Biozym 
Ampicillin        Sigma-Aldrich 
(2R)-amino-5-phosphonovaleric acid (AP5)    Tocris 
Aqua-Poly/Mount        Polysciences 
LB-Agar        Sigma-Aldrich 
LB-Broth        Carl Roth 
β-Mercaptoethanol          Sigma-Aldrich 
N,N-Bis-(2-Hydroxyethyl)-2-Aminoethane Sulfonic Acid (BES)  FA Applichem 
Bovine serum albumin (BSA)      New England Biolabs 
Brain derived neurotrophic factor (BDNF)     Peprotech 
Bromophenol blue          Sigma-Aldrich 
Calcium chloride (CaCl2)      Carl Roth 
1,4-Dithiothreitol (DTT)      Sigma-Aldrich 
DNA Gel Loading Dye       Thermo Scientific 
Dulbecco's Phosphate-Buffered Saline (DPBS)   Life Technologies 
Ethylenediaminetetraacetic acid (EDTA)    Sigma-Aldrich  
Ethidium bromide (EtBr)      Carl Roth  
5-fluorodeoxyuridine (FUDR)     Sigma-Aldrich  
Glucose        Sigma-Aldrich 
Hydrochloric acid (HCL)      Carl Roth 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Sigma-Aldrich 
Hoechst        Invitrogen 
Kanamycine        Sigma-Aldrich 
Laminin         BD Biosciences 
LB Broth        Sigma-Aldrich 
Lipofectamine 2000        Invitrogen 
Magnesium acetate (MgAc)      Fisher Scientific 
Magnesium chloride (MgCl2)     Carl Roth 
Methanol        VWR Chemicals 
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Milk powder        Carl Roth 
NP-40 (Igepal)       Sigma-Aldrich 
OptiPrep™ Density Gradient Medium    Sigma-Aldrich 
Paraformaldehyde       Carl Roth  
Poly-L-Lysine        Sigma-Aldrich 
Poly-L-Ornithine        Sigma-Aldrich 
Potassium acetate (KAc)      Carl Roth 
Potassium chloride (KCl)      Carl Roth 
Potassium hydroxide (KOH)      Carl Roth 
Precision Plus Protein Dual Color Standard     Bio-Rad 
Sodium chloride (NaCl)      Carl Roth 
Sodium deoxycholate (NaDOC)     Sigma-Aldrich 
Sodium dodecyl sulfate (SDS)     Carl Roth 
Sucrose        Carl Roth 
Tris(hydroxymethyl)aminomethane (Tris)    Carl Roth 
Triton X-100        Carl Roth 
Tween 20        Carl Roth 
yeast tRNA         Sigma-Aldrich 
2.1.2  Enzymes and inhibitors  
Restriction enzymes 
AscI, EcoRI, HindIII       New England Biolabs  
BamHI , BsrGI, DpnI, MssI, NotI, SacI, XbaI   Thermo Scientific 
 
Other enzymes 
Benzonase® Nuclease      Sigma-Aldrich 
DNA Polymerase I, Large (Klenow) Fragment   New England Biolabs 
PfuPlus! DNA Polymerase       Roboklon 
RNase A         Ambion 
Shrimp alkaline phosphatase      Promega 
T4 DNA ligase        Invitrogen 
Turbo DNase         Ambion 
 
Inhibitors 
Complete Protease inhibitors      Roche 
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Phosphatase inhibitors cocktail 2 and 3     Sigma-Aldrich 
SUPERase inhibitor        Ambion 
2.1.3  Lab equipment 
Amicon Ultra-15 centrifugal filter with Ultracel-100 membrane Merck Millipore 
Cell culture dishes (15 cm2)      Corning 
Cell culture flasks (25, 75, 175 cm2)     Sarstedt  
Cell culture plates (24-well, 6-well)      Corning 
Cell-lifter        Corning 
Centrifuge JC-MC       Beckman Coulter 
Coverslips        Carl Roth 
Curix 60 Tabletop processor      Agfa 
Digital gel documentation system E-Box    Vilber 
Dounce potter (15 ml)      Sartorius 
Eppendorf reaction tubes (1.5 ml/2 ml)    Eppendorf 
GloMax R96 Microplate Luminometer     Promega 
Hyperfilm ECL       GE Healthcare 
Intell Mixer RM-2L       Elmi 
LSM 5 Pascal microscope      Zeiss 
Magnetic Particle Concentrator DynaMagTM -2   Invitrogen 
Microscope slides        neoLab 
Microtiter plate (96-well)      Nunc  
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell  Bio-Rad 
Nano Drop 2000c       Thermo Scientific 
Needle (26G)        B.Braun 
Protein G beads        Sigma-Aldrich 
Protein G Dynabeads®       Life technologies 
PVDF membrane        Millipore 
Rotor type 70 Ti       Beckman Coulter 
Sonifier 250         Branson 
Step One Plus instrument       Applied Biosystems 
Thermal cycler S1000TM      Bio-Rad 
Tubes type 70 Ti        Beckman Coulter 
Ultracentrifuge Optima XE-90     Beckman Coulter 
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2.1.4  Kits 
Amersham ECL Prime Western Blotting Detection Reagent GE Healthcare 
Dual-Luciferase® Reporter Assay System    Promega 
iScript cDNA synthesis Kit       Bio-Rad 
iTaq SYBR Green Supermix with ROX     Bio-Rad 
mirVanaTM Isolation Kit       Ambion 
NucleoBond® Xtra Midi Kit      Macherey-Nagel 
Pierce™ BCA Protein Assay Kit      Thermo Scientific 
QIAquick Gel Extraction Kit      Qiagen 
QIAquick Purification Kit      Qiagen 
2.1.5  Buffers and solutions  
2x HBS: 
 
50 mM HEPES 
10 mM KCl 
12 mM Glucose 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 7.05 
 
2x BBS: 
 
50 mM BES  
1.5 mM Na2HPO4  
280 mM NaCl 
pH 6.95 
 
Tris/NaCl: 
 
50 mM Tris 
150 mM NaCl 
pH 8.0 
 
PBS-MK: 
 
1 x DPBS 
1 mM MgCl2 
2.5 mM KCl 
 
5x Annealing buffer:  
  
100 mM KAc 
30 mM HEPES-KOH, pH 7.4 
2 mM MgAc 
 
50x TAE buffer: 2 M Tris-acetate    
50 mM EDTA   
 
KCM solution: 100 mM KCL 
30 mM CaCl2 
50 mM MgCl2 
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HLB: 
 
10 mM KCL  
1 mM EDTA  
1 mM DTT 
10 mM Tris-HCl  
pH 7.5  
 
10x RIPA: 
 
0.5 M Tris pH 8.0 
1.5 M NaCl 
10% Triton X-100 
5% NaDOC 
0.5% SDS 
20 mM EDTA 
 
lysis buffer (protein extraction): 
 
150 mM NaCl 
50 mM Tris pH 7.5 
1% Triton X-100 
 
4x Laemmli sample buffer: 250 mM Tris-HCl (pH 6.8)    
8% SDS    
40% glycerol    
8% β-mercaptoethanol    
0.04% bromophenol blue    
 
TBS-T: 50 mM Tris 
150 mM NaCl    
0.1% Tween 20  
pH 7.5 
 
Running buffer: 25 mM Tris    
192 mM glycine   
0.1% SDS    
 
Blotting buffer:   25 mM Tris    
192 mM glycine    
20% methanol    
 
lysis buffer (co-IP): 
 
20 mM Tris pH 7.5 
150 mM NaCl 
1% NP-40 
2 mM EDTA 
 
lysis buffer (RNA-IP): 
 
10 mM HEPES, pH 7.5  
200 mM NaCl 
30 mM EDTA 
0.5% Triton X-100 
0.5 U/µl SUPERase inhibitor 
 
GDB: 
 
20 mM Sodium phosphate buffer, pH 7.4 
450 mM NaCl 
0.3% Triton X-100 
0.1% gelatine 
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2.1.6  Cells and culture media  
Prokaryotic cells 
Escherichia coli (E. coli) (XL1-Blue) 
LB medium:  LB-Broth 
 
LB Agar plates: 1.5% LB-Agar in LB medium 
 
Eukaryotic cells 
Human embryonic kidney 293 (HEK293) cells 
Growth medium:  Minimum essential medium (MEM) Gibco 
10% fetal calf serum (FCS)  Invitrogen 
2 mM L-Glutamine    Invitrogen 
100 U/ml Penicillin/Streptomycin  Invitrogen 
 
Primary neuronal cells prepared from embryonic day 18 Sprague Dawley rats (Charles 
River Laboratories) 
Growth medium (NB+): Neurobasal medium (NB)  Invitrogen 
2% B27 supplement   Invitrogen 
1 mM GlutaMax   Invitrogen 
100 U/ml Penicillin/Streptomycin  Invitrogen 
  
2.1.7  Oligonucleotides  
Oligonucleotide sequences are notated from 5’ to 3’ direction. 
Primers used to clone 3’UTRs to pGL4: 
LIN41-FW   GATCTCTAGACACTTTCTTCTTGCTCTTTAC 
LIN41-REV   GATCGCTAGCTTTATTCCAATTATGTTATCAG 
LIMK1-FW   CTTCTAGAGATACTTGGAGGATAGACCCTCACC 
LIMK1-REV   GCCCCGACTCTAGCTAGCGGGAGCACAGAATTGAT 
Primers used for site directed mutagenesis: 
Nova1R-FW   GATTTTTATCCAGGTACCACCGAGCGGGTTTGCTTGATCCAGG 
Nova1R-REV              CCTGGATCAAGCAAACCCGCTCGGTGGTACCTGGATAAAAATC 
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Oligonucleotides used for cloning rAAV-Nova1 shRNA: 
Nova1-shRNA-fw1  GATCCCCGGTACTACTGAGAGGGTTTTCAAGAGA 
Nova1-shRNA-fw2  AAACCCTCTCAGTAGTACCTTTTTA 
Nova1-shRNA-rev1  AGCTTAAAAAGGTACTACTGAGAGGGTTTTCTCTTGAA 
Nova1-shRNA-rev2  AAACCCTCTCAGTAGTACCGGG 
Primers used for cloning of NHA-fusion constructs: 
NHA-Nova1-Xba1-FW           TCTCTAGAATGGCGGCAGCTCCCATTCAGCAGAACG 
NHA-Nova1-Not1-REV    CCGGTGGCGGCCGCGTCAACCCACTTTCTGAGGATTGGCAG 
NHA-Nova1-del1-Not1-REV  CTGTGGATCCTCTGCGGCCGCCTGCTAGATAAGTTCAACAG 
NHA-Nova1-del2-Xba1-FW   TGAATCTAGAATCCAGAAGATACAAGAGGATCCACAGAGTG 
NHA-EGFP-FW     CCACCGGTCGACACCATGGTGAGCAAGGGCG 
NHA-EGFP-REV     ATCTAGAGTCGCGGCCGCTTTACTTGTAC 
Primers used for qPCR: 
U6 snRNA FW  CTCGCTTCGGCAGCACA 
U6 snRNA REV  AACGCTTCACGAATTTGCGT 
GAPDH FW   GCCTTCTCTTGTGACAAAGTGGA 
GAPDH REV  CCGTGGGTAGAGTCATACTGGAA 
Limk1 FW   CCTCCGAGTGGTTTGTCGA 
Limk1 REV   CAACACCTCCCCATGGATG 
Rgs4 FW   ACAAGCCGGAACATGTTAGAG 
Rgs4 REV   AGACTTGAGGAAACGACGGT 
 
2.1.8  RNA molecules 
Table 1: MiRNA sense and antisense sequences  
miRNA Sequence (5’ – 3’) 
miR-134 sense Phospho-UGUGACUGGUUGACCAGAGGGA 
miR-134 antisense Phospho-CCUCUGGUCAACCAGUUAUACU 
miR-138 sense Phospho-AGCUGGUGUUGUGAAUCAGGCCG 
miR-138 antisense Phospho-GCCUGAUUCACAACACCAGAUUU 
 
MiRNA sense and antisense oligos (Table 1) (Integrated DNA Technologies) were used 
for miRNA duplex annealing (chapter 2.3.1). 
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Table 2: SiRNA subset of custom siRNA library (Ambion) 
siRNA siRNA sense sequence siRNA antisense sequence 
Ewsr1 siRNA-1 GGAUAUGCACAGACCACCCtt  GGGUGGUCUGUGCAUAUCCtt 
Ncoa3 siRNA-2 GGAGACAGUGAGACAGAUAtt UAUCUGUCUCACUGUCUCCtt 
Nova1 siRNA-3 GGUACUACUGAGAGGGUUUtt AAACCCUCUCAGUAGUACCtg 
Nxf1 siRNA-1 CGAUUUCCCAAGUUAUUACtt  GUAAUAACUUGGGAAAUCGtt 
Nxt1 siRNA-2 GCCACUUUAGUAUGGAAUGtt  CAUUCCAUACUAAAGUGGCtg 
Rbm25 siRNA-2 GGACAUUUUCCGUAGAUUUtt  AAAUCUACGGAAAAUGUCCtc 
Rpl5 siRNA-3 GGAGAUGUAUAAGAAAGCUtt AGCUUUCUUAUACAUCUCCtc 
Tnrc6c siRNA-3 GGUUCAAGCACAGCUUUUGtt CAAAAGCUGUGCUUGAACCtg 
U2af1 siRNA-2 CCUUUAGCCAGACCAUUGCtt  GCAAUGGUCUGGCUAAAGGtt 
 
2.1.9  Plasmids 
Luciferase reporter plasmids 
The pGL4.13 vector (Promega) encodes the luciferase reporter gene luc2 (firefly). The 
vector contains an SV40 early enhancer/promoter. The firefly reporter constructs were 
generated by PCR amplification and/or restriction digest of the corresponding 3’UTRs 
(Table 3) from pGL3-3’UTR reporter constructs. The 5’overhangs of the resulting inserts 
were filled by Klenow reaction (chapter 2.3.5). The 3’UTRs were inserted downstream 
of the firefly gene into the XbaI restriction site of pGL4.13. The 138-sponge-luc reporter 
was generated by inserting six binding sites for miR-138 carrying a bulge at position 9-
12 (Ebert et al. 2007) into pGL4.13 vector. The control (ctrl) sponge was created by 
inserting the reverse sequence of the 138 sponge into pGL4.13.  
In order to generate the renilla luciferase vector pGL4-RL, the renilla luciferase gene was 
excised by restriction digest from the plasmid phRL-TK and inserted into pGL4.13 by 
replacing the firefly coding sequence. 
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Table 3: Luciferase reporter plasmids 
Luciferase reporter 
plasmid  
3’UTR / Reference Restriction sites used 
for cloning 3’UTR 
pGL4-UBE3A UBE3A rat (606 bp) (Valluy et 
al. 2015) 
BamHI, XbaI 
pGL4-APT1 APT1 mouse (Siegel et al. 2009) AscI, EcoRI 
pGL4-LIN41-WT LIN41 C. elegans (D. Bartel) NotI, MssI 
pGL4-LIN41-mutant LIN41 C. elegans (D. Bartel) NotI, MssI 
pGL4-LIMK1-WT LIMK1 rat (Schratt et al. 2006) XbaI, NheI 
pGL4-LIMK1-mutant LIMK1 rat (Schratt et al. 2006) XbaI, NheI 
pGL4-IQGAP1-WT IQGAP1 human (D. Bartel) SacI, XbaI 
pGL4-IQGAP1-mutant IQGAP1 human (D. Bartel) SacI, XbaI 
pGL4-HMGA2-WT HMGA2 mouse (D. Bartel) XbaI, NotI 
pGL4-HMGA2-mutant HMGA2 mouse (D. Bartel) XbaI, NotI 
pGL4-138-sponge 6x miR-138 binding site (S. 
Bicker, K. Weiß) 
BsrGI, HindIII 
pGL4-ctrl-sponge 6x miR-138 binding site reversed 
(S. Bicker, K. Weiß) 
BsrGI, HindIII 
 
ShRNA expression plasmids  
In order to generate shRNA expression vector pAAV-Nova1 shRNA, DNA 
oligonucleotides (chapter 2.1.7) were annealed followed by ligation into the BglII and 
HindIII restriction sites of the pAAV vector (Christensen et al. 2010). The pAAV vector 
contains inverted terminal repeats (ITRs) that flank a U6 promoter driven shRNA 
sequence upstream of a chicken β-actin (CBA) promotor driven GFP gene. 
Table 4: ShRNA expression plasmids 
shRNA expression plasmid Reference 
pSuper basic Oligoengine 
pSuper-control shRNA Störchel and Thümmler et al. 2015 
pSuper-Nova1 shRNA Störchel and Thümmler et al. 2015 
pAAV-control shRNA pAM/U6-sHRNA-EGFP-CBA-hrGFP 
(obtained from M. Schwarz) 
pAAV-Nova1 shRNA generated from pAAV-control shRNA  
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GFP-Nova1 overexpression vector 
To generate the vector expressing an shRNA-resistant Nova1 protein (Nova1R), silent 
mutations were introduced into the GFP-Nova1 expressing vector pEGFP-C1-Nova1 (G. 
Siegel) by site directed mutagenesis (chapter 2.3.8) using the primer Nova1R-FW and 
Nova1R-REV resulting in the vector pEGFP-C1-Nova1R. 
Table 5: GFP-Nova1 overexpression plasmids 
GFP-Nova1 overexpression plasmid Reference 
pEGFP-C1 Clontech 
pEGFP-C1-Nova1 Störchel and Thümmler et al. 2015 
pEGFP-C1-Nova1R generated from pEGFP-C1-Nova1 
 
Plasmids for tethering assay 
To generate pCI-neo-NHA-Nova1 and pCI-neo-NHA-GFP, the respective coding 
sequences were amplified by PCR from the vector pEGFP-C1-Nova1 and pEGFP-N1. 
Subsequently, the PCR product was inserted into the vector pCI-Neo-NHA downstream 
of the N-HA peptide sequence by use of the restriction sites that are indicated in the primer 
name (chapter 2.1.7). 
Table 6: Plasmids used for tethering assays 
Tethering assay plasmid Reference 
RL-5boxB obtained from R. Pillai 
pCI-neo-NHA obtained from R. Pillai 
pCI-neo-HA-Tnrc6c obtained from R. Pillai 
pCI-neo-NHA-Tnrc6c obtained from R. Pillai 
pCI-neo-NHA-Nova1 generated from pCI-Neo-NHA 
pCI-neo-NHA-GFP generated from pCI-Neo-NHA 
pCI-neo-NHA-Ncoa3 Störchel and Thümmler et al. 2015 
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2.1.10  Antibodies 
Table 7: Antibodies used for Western blot (WB), immunocytochemistry (ICC), RNA-IP and co-IP 
Antibody Species Source Application/ 
Dilution 
Primary antibodies 
anti-MAP2 mouse clone HM-2, Sigma-Aldrich ICC/ 1:2,000 
anti-α-Tubulin rabbit cat.# 2144, Cell Signaling  WB/ 1:5,000 
anti-β-Actin mouse clone AC-15, Sigma-Aldrich WB/ 1:10,000 
anti-HDAC2 rabbit ab32117, Abcam WB/ 1:5,000 
anti-Limk1 mouse clone 42, BD Biosciences WB/ 1:200 
anti-Nova1 rabbit Merck Millipore cat.# 07-
637 
WB/ 1:1,500;  
ICC/ 1:250 
anti-Nova1 rabbit ab183723, Abcam RNA-IP 
anti-Nova-pan rabbit obtained from R. Darnell WB/ 1:5,000 
anti-pan-Ago mouse clone 2A8, Merck Millipore co-IP/ 1:200 
anti-Ago2 rat clone 6F4, obtained from G. 
Meister 
WB/ 1:10 (serum) 
anti-HA rabbit ab9110, Abcam ICC/ 1:1,000 
rabbit IgG normal Santa Cruz Biotechnology RNA-IP 
mouse IgG normal Santa Cruz Biotechnology co-IP 
Secondary antibodies 
anti-mouse HRP rabbit Calbiochem WB/ 1:20,000 
anti-rabbit HRP goat Calbiochem WB/ 1:20,000 
anti-rat HRP goat Calbiochem WB/ 1:20,000 
Alexa 488 anti-rabbit goat Life technologies ICC/ 1:1,000 
Alexa 647 anti-mouse donkey Life technologies ICC/ 1:1,000 
Alexa 546 anti-mouse goat Life technologies ICC/ 1:1,000 
2.2 Cell culture methods 
2.2.1  Primary neuronal cell culture 
Dissociated primary cortical and hippocampal neurons were prepared from embryonic 
day 18 rats as described in Schratt et al. (2004). After dissociation cortical neurons were 
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directly plated on Poly-L-Ornithine (Sigma) coated 24-well or 6-well cell culture plates. 
Hippocampal neurons were plated on nitric acid-treated coverslips that were coated with 
Poly-L-Lysine and Laminin in a 24-well format. Both types of primary neurons were 
cultured in Neurobasal medium (NB+) at 37 °C and 5% CO2. Primary neurons were 
routinely prepared by Gertraud Jarosch, Eva Becker, Renate Gondrum and Heinrich 
Kaiser. 
For the analysis of subcellular fractions, hippocampal neurons were cultured in medium 
supplemented with 10 µM of 5-fluorodeoxyuridine (FUDR) to prevent the growth of glial 
cells. For BDNF stimulation, cortical neurons were treated with BDNF at a final 
concentration of 100 ng/ml for 5 min to 5 h before cell lysis. 
2.2.2  Human embryonic kidney 293 cell culture 
Human embryonic kidney 293 (HEK293) cells were cultivated in 6-well- or 12-well-
culture plates at subconfluent density in minimum essential medium (MEM) 
supplemented with FCS, L-Glutamine and Penecillin/Streptomycin at 37 °C and 5% CO2.  
2.2.3  Transfection of neurons with Lipofectamine 2000 
Cultured neuronal cells were transfected with the Lipofectamine 2000 transfection 
reagent. Per well (24-well format), a total of 1 µg of RNA or DNA was mixed with a 1:66 
dilution of Lipofectamine 2000 in 100 µl Neurobasal medium (NB, without supplements). 
The mixture was incubated at room temperature (RT) for 20 min, then diluted 1:5 in NB 
medium and gently applied to the cells. After 2 h of incubation at 37 °C and 5% CO2, the 
cells were washed with NB. Subsequently, the cells were incubated with the NMDA-
receptor antagonist (2R)-amino-5-phosphonovaleric acid (AP5, 20 µm) in NB+ for 45 
min at 37 °C. After an additional washing step with NB the cells were provided with one 
third of fresh NB+ medium mixed with two third of medium cells were incubated in 
before (conditioned medium) that was collected before the transfection procedure. 
2.2.4  Transfection of HEK293 cells with calcium-phosphate  
HEK293 cells were transfected at a confluency of 60% using calcium-phosphate. Per well 
(12-well format) a total amount of 3.2 µg of DNA was mixed with 6 µl of 2 M CaCl2 in 
H2O (total volume of 50 µl). Then 50 µl of 2x HBS were added to the mixture while 
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slowly vortexing. The mix was incubated for 3 min at RT and gently applied drop-wise 
to the cells medium. After 5 h incubation at 37 °C and 5% CO2 the medium was replaced 
with fresh MEM. The cells were lysed after incubation for 18-24 h. 
2.2.5  Production of recombinant adeno-associated virus (rAAV)  
Recombinant adeno-associated viruses (rAAV) expressing either Nova1 shRNA or 
control shRNA were generated by co-transfection of the shRNA expressing pAAV 
plasmid and the helper plasmids pDP1 and pDP2 (Grimm et al. 2003) into HEK293 cells 
using calcium-phosphate. The cells were plated onto 15 cm2 cell culture dishes and 
transfected at 80% confluency. The DNA mix was prepared for a total of 8 dishes (96 µg 
pAAV, 192 µg pDP1, 192 µg pDP2) and mixed with 2.5 ml 2 M CaCl2 and 17.5 ml H2O. 
After splitting the solution to 8 vessels (2.5 ml each) 2.5 ml of 2x BBS were added. The 
solution was gently mixed by inverting the tube and incubated at RT for 3 min.  20 ml of 
MEM were added and the mixture was applied to the cells after removing the complete 
culture medium. Following 5 h of incubation at 37 °C and 5% CO2, the cells were washed 
with 25 ml fresh MEM. After 3 days, the cells were harvested with a cell-lifter and 
collected in 4 tubes. The pelleted cells from 8 plates were united in 25 ml DPBS and 
resuspended in 8.5 ml Tris/NaCl. 2 µl of Benzonase (25 U/µl) were added followed by 
500 µl of 10% NaDOC. After incubation for 30 min at 37 °C 584 mg NaCl were dissolved 
in the cell solution followed by 30 min of incubation at 56 °C. The cells were frozen 
overnight at -20 °C, thawed and centrifugated for 30 min at 16,000 g. After another 
freeze-thaw cycle the virus was purified by discontinuous iodixanol gradient 
centrifugation (Zolotukhin et al. 1999). The sample was loaded onto the gradient (7 ml 
of 15%, 4 ml of 25%, 3 ml of 40% and 3 ml of 54% iodixanol) in 70 Ti rotor tubes and 
spun in the ultracentrifuge for 2 h at 55,000 rpm (rotor type 70 Ti). To recover the virus, 
the 40% phase and interphase between 40% and 54% were aspirated with a syringe and 
1:1 diluted in PBS-MK. The virus was concentrated through filter (Amicon Ultra-15 
centrifugal filter with Ultracel-100 membrane) by centrifugation at 2,000 g.  
2.2.6  rAAV infection of neurons 
In order to yield a high number of shRNA expressing cells in the neuronal culture, cells 
were infected with shRNA expressing recombinant adeno-associated virus (rAAV). 
Cortical neurons were infected at 4 days in vitro (DIV) with shRNA expressing rAAV 
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(2*106 IFU (infectious units)/ml). Virus infected cells were lysed 10 days after infection 
(14 DIV).  
2.3  Molecular methods 
2.3.1  Annealing of miRNA duplex 
MiRNA duplex RNA was synthesized by annealing single stranded miRNA sense and 
miRNA antisense strands (Table 1). 20 µl of each strand (100 µM) were mixed with 10 
µl 5x Annealing buffer. The mixture was incubated in the thermal cycler for 2 min at 95 
°C, for 1 h at 37 °C and cooled down to 4 °C.  
2.3.2  Polymerase chain reaction (PCR) 
The amplification of specific DNA fragments for cloning was performed by polymerase 
chain reaction (PCR) using the PfuPlus! DNA Polymerase. In accordance with the 
manuals’ instruction, PCR reactions were set up as follows and incubated in a thermal 
cycler with the following program. 
PCR reaction (50 µl): 
5 µl 10x Pfu buffer  
4 µl 2.5 mM dNTP mix 
2 µl 10 µM forward primer  
2 µl 10 µM reverse primer 
1 µl plasmid DNA (50 ng)  
0.5 µl PfuPlus! DNA polymerase (2.5 U) 
35.5 µl ddH2O   
PCR program: 
Initial denaturation 95 °C, 3 min 
Denaturation           95 °C, 50 sec 
Annealing               50 - 68 °C, 30 sec    35 x 
Extension                72 °C, 1 min/kb 
Terminal extension 72 °C, 7 min 
                                  4 °C, ∞ 
 
2.3.3  Agarose gel electrophoresis  
The separation of DNA fragments according to their size was performed by agarose gel 
electrophoresis. The DNA samples were mixed with DNA Gel Loading Dye (Thermo 
ScientificTM) and loaded onto a 1% agarose gel in 1x TAE buffer containing ethidium 
bromide (1:200). The gel was run at 120 V. The bands were visualized by UV-light in a 
digital gel documentation system. 
 MATERIALS AND METHODS 
37 
 
2.3.4  Purification of plasmid DNA and PCR products 
Restricted DNA fragments were separated by agarose gel electrophoresis and the  
respective bands were excised from the gel followed by purification using the QIAquick 
Gel extraction kit. PCR products were purified by use of the QIAquick purification kit 
according to the manuals’ instructions. 
2.3.5  Restriction digest, dephosphorylation, Klenow reaction and ligation of DNA  
For cloning of recombinant DNA constructs, plasmid DNA or PCR-products were 
digested with restriction enzymes (chapter 2.1.2) according to the manuals’ instructions.  
In order to generate blunt ends of fragments, 5’-overhangs were filled up by Klenow 
reaction. DNA polymerase I, large (Klenow) fragment was used according to the 
manufactures’ protocol (1U/µg DNA). 
To prevent self-ligation of the linearized vector, DNA was dephosphorylated using 
shrimp alkaline phosphatase to prevent self-ligation. 
The ligation of DNA fragments into linearized vector DNA was performed using the T4 
DNA ligase in accordance with the manuals’ instructions. The dephosphorylated, 
linearized vector DNA was mixed with restricted insert DNA at a ratio of 1:3 for sticky 
end ligation or 1:5 for blunt end ligation.  
2.3.6  Transformation of competent bacteria 
Transformation of chemical competent E. coli cells was performed by heat shock. Cells 
were thawed on ice and 1:1 diluted in KCM solution. 100 µl of the cell solution were 
mixed with 10 ng plasmid DNA or 1 µl ligation mixture. Following heat shock for 45 sec 
at 42 °C, cells were chilled on ice for 10 min. In the case of ampicillin-resistant plasmids, 
the transformed cells were directly plated onto LB plates containing 100 µl/ml ampicillin. 
In case of kanamycin-resistant plasmids, 1 ml of pre-warmed antibiotic-free LB was 
added to the cell suspension and the mixture was shaken for 1 h at 37 °C. The cells were 
centrifuged for 3 min at 1,200 g and the pellet was resuspended in 100 µl LB. The 
suspension was plated on LB plates containing 50 µl/ml kanamycin. The plates were 
incubated over night at 37 °C. 
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2.3.7  Plasmid midi preparation 
Plasmids for midi preparation were isolated from transformed E. coli. A single bacteria 
colony was inoculated in 200 ml of antibiotic supplemented LB medium and grown over 
night at 37 °C. The cell suspension was pelleted by centrifugation at 4 °C. The preparation 
of plasmids was performed using the NucleoBond® Xtra midi kit according to the 
manuals’ instructions. Plasmid concentrations were measured with a Nano Drop 2000c. 
2.3.8  Site-directed mutagenesis 
The introduction of point mutations in the DNA sequence of a plasmid was generated by 
PCR, based on the manufacturer’s instructions of the Quick Change® Site directed 
mutagenesis kit (Stratagene). The PCR reaction was set up as follows and incubated in a 
thermal cycler with the following program. 
PCR reaction (50 µl): 
5 µl 10x Pfu buffer  
4 µl 2.5 mM dNTP mix 
1,25 µl forward primer (125 ng)  
1,25 µl reverse primer (125 ng)  
1 µl plasmid DNA (12.5 ng)  
0.5 µl PfuPlus! DNA polymerase (2.5 U) 
37 µl ddH2O   
PCR program: 
Initial denaturation 95 °C, 1 min 
Denaturation           95 °C, 30 sec 
Annealing               55 °C, 1 min        18 cycles 
Extension                68 °C, 1 min/kb 
Terminal extension 68 °C, 7 min 
 
 
To cleave the template plasmid, the PCR reaction was then digested with DpnI (10 U) for 
1 h at 37 °C. 1 µl of digested PCR product was transformed into bacteria. 
2.3.9  cDNA synthesis and RT-qPCR 
Complementary DNA (cDNA) was synthesized from purified DNA-free RNA samples 
by reverse transcription. 1 µg total RNA was reverse transcribed using the iScript cDNA 
synthesis Kit and additional MgCl2. The reaction mix was incubated in a thermal cycler 
according to the manufactures’ instructions. The cDNA was diluted 1:5 in nuclease-free 
water. Real time-quantitative PCR (RT-qPCR) was processed in duplicates using the iTaq 
SYBR Green Supermix with ROX according to the manufactures’ protocol. The PCR run 
was performed on a Step One Plus instrument. 
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cDNA synthesis reaction (20 µl): 
4 µl 5x iScript reaction mix 
1 µl 100 mM MgCl2 
1 µl iScript reverse transcriptase 
14 µl RNA template 
 
cDNA reaction program: 
25 °C, 5 min 
42 °C, 30 min 
85 °C, 5 min 
4 °C, ∞ 
RT-qPCR reaction (20 µl): 
10 µl iTaq SYBR Green supermix 
0.5 µl 10 µM forward primer 
0.5 µl 10 µM reverse primer 
4 µl nuclease-free dH2O 
5 µl cDNA 
RT-qPCR program: 
95 °C, 3 min 
95 °C, 15 sec     45 cycles 
60 °C, 30 sec 
2.4  Biochemical methods 
2.4.1  Subcellular fractionation  
For the subcellular fractionation of lysates from hippocampal neurons, the cells were 
washed with ice-cold DPBS and detached in HLB containing protease inhibitors and 0.2 
%NP-40 by shaking for 10 min at 4 °C. The cell lysis was achieved through 20 strokes 
with a Teflon potter. One part of the sample was taken as input and diluted with 10x RIPA 
buffer to 1x. For nuclear and cytosolic fractions, the lysate was centrifugated at 800 g for 
5 min at 4 °C. The supernatant was recovered as cytosolic fraction. The pellet that 
contains the nuclei was washed once with HLB containing 0.25 M sucrose and dissolved 
in 1x RIPA (containing protease inhibitors). The input and nuclear sample were lysed by 
sonication. Subsequently, all fractions were centrifugated by 16,000 g for 10 min at 4 °C 
and the respective supernatants were recovered as protein extracts. The subcellular 
fractionation was performed by Peter Störchel. 
2.4.2  Protein extraction 
For the preparation of whole cell lysates from neurons, cells were washed once with 
DPBS and resuspended in lysis buffer containing protease inhibitors. BDNF-treated 
neurons were lysed in lysis buffer additionally containing Phosphatase Inhibitors Cocktail 
2 and 3.  
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2.4.3  Western blot analysis 
The protein concentration of cell extracts was determined using the Pierce™ BCA Protein 
Assay Kit. Equal protein amounts or lysate volumes were mixed with Laemmli sample 
buffer, boiled for 5 min at 95 °C and loaded onto a 10% SDS-polyacrylamide gel and 
separated by electrophoresis (SDS-PAGE) in running buffer. Precision Plus Protein Dual 
Color Standard was loaded as size standard next to the samples. The proteins were then 
transferred by tank blotting at 90 V and 4 °C for 100 min in blotting buffer to an 
Amersham Hybond PVDF (poly-vinylidene difluoride) membrane, which was prior 
activated in 100% methanol. To saturate unspecific binding, the membrane was incubated 
on a shaker for 1 h with 5% milk powder in TBS-T. The blot was then incubated with a 
primary antibody (Table 7) diluted in milk containing TBS-T for 2-3 h at RT or overnight 
at 4 °C. After three times washing for 10 min at RT with TBS-T milk, the blot was 
incubated with the HRP-conjugated secondary antibody (Table 7) for 1 h at RT, followed 
by three wash steps with TBS-T. HRP was detected using the ECL Prime Western 
Blotting Detection Reagent. The band intensities of scanned films were measured with 
ImageJ software. 
2.4.4  Luciferase reporter assay 
Luciferase reporter assays were performed by use of the Dual Luciferase Reporter 
System. Therefore, hippocampal neurons (11 DIV) or cortical neurons (5 DIV, 12 DIV) 
were transfected in 24 well-plates with equal amounts of firefly (pGL4-3’UTR reporter 
constructs) and renilla luciferase (pGL4-RL) expressing vectors (Table 3). The luciferase 
vectors were co-transfected in duplicates as indicated with either pSuper vector (Table 4) 
or siRNA duplex (Table 2) for knockdown of RBPs, and in the case of miRNA 
overexpression with miRNA duplex RNA (miR-134 or miR-138) (Table 1). After 2-3 
days the cells were washed once in 500 µl DPBS. The DPBS was replaced by 100 µl/well 
of 1x lysis buffer (Promega) and lysis was carried out by shaking the plate for 20 min at 
RT. The solutions for the firefly and renilla luciferase measurement were prepared as 
indicated in the manufactures instructions. After the lysis, 20 µl of each lysate were 
transferred to a 96-well microtiter plate. The luciferase activity of both firefly and renilla 
was measured using the GloMax R96 Microplate Luminometer. Firefly activity was 
normalized to renilla activity and a basal condition which did not contain an shRNA 
expression vector or an siRNA duplex was set as 1.0 RLA (relative luciferase activity).  
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Table 8: Vector and RNA duplex quantities used for transfection 
2.4.5  Tethering assay 
Tethering experiments were performed by co-transfecting cortical neurons at 5 DIV with 
150 ng pCI-Neo-NHA or 250-400 ng NHA-fusion constructs, 50 ng of pRL-5boxB and 
50 ng of pGL4.13. The cell lysis and luciferase measurement was performed 2 days after 
transfection as described in chapter 2.4.4. The renilla activity was normalized to firefly 
activity. 
2.4.6  Co-immunoprecipitation (co-IP) 
Co-immunoprecipitation (co-IP) of Ago and Nova1 was performed in lysates that were 
prepared from hippocampi of adult female rat brain. The hippocampi of one brain were 
dissected in ice-cold DPBS and transferred to a pre-chilled 15 ml dounce potter and 
homogenized on ice by 14 strokes in 2.5 ml lysis buffer containing protease inhibitors. 
The homogenate was transferred to 2 ml tubes and centrifugated for 10 min at 16,000 g 
at 4 °C. 50 µl of the supernatant were kept as input, the rest was used for further steps. 
For RNase treatment RNase A (1:20) was added to one half of the cell lysate. For 
immunoprecipitation of Ago 500 µl lysate were incubated with mouse anti pan-Ago (1.25 
µg). As a control, 500 µl lysate were incubated with mouse IgG (1.25 µg). Antibody 
incubation occurred in Eppendorf tubes rotating over night at 4 °C. Protein G beads (25 
µl per condition) were equilibrated in lysis buffer by rotating for 5 min at 4 °C followed 
by centrifugation for 2 min at 300 g (twice). Afterwards the beads were blocked for 2 h 
in BSA diluted in lysis buffer (1 mg/ml). Following two times washing in 1 ml lysis 
buffer, the beads were resuspended in 30 µl lysis buffer and incubated with lysate and 
antibody for 1 h at 4 °C followed by four washes in lysis buffer. The last two wash steps 
contained 350 mM NaCl. After final washing the supernatant was discarded and beads 
were mixed with sample buffer and prepared for SDS-PAGE. 
Plasmid/ duplex RNA Amount per well (24-well format) 
pGL4-3’UTR 50 – 100 ng 
pGL4-RL 50 – 100 ng 
pSuper 10 ng 
siRNA duplex 7.5 pmol 
miRNA duplex 5 pmol 
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2.4.7  RNA-immunoprecipitation (RNA-IP) 
The hippocampi of an adult female rat were dissected and homogenized in a dounce potter 
by 20 strokes in 3.5 ml lysis buffer containing complete protease inhibitors. The 
homogenate was then passed five times through a 26G needle. After centrifugation for 20 
min at 70,000 g at 4 °C, the supernatant was supplemented with 100 µg/ml yeast tRNA. 
Protein G Dynabeads were equilibrated in 1 ml lysis buffer (without inhibitors) by 
rotating for 5 min at 4 °C. To separate the beads from the solution, the tube was placed 
on a magnet and the supernatant was removed. The lysate was then precleared with the 
beads for 30 min at 4 °C. After preclearing, 160 µl of the supernatant were collected as 
input. The immunoprecipitation was performed by addition of 10 µg antibody (rabbit anti-
Nova1(Abcam) or normal rabbit IgG (SCBT)) and 30 µl Protein G Dynabeads to 1 ml of 
precleared lysate. The solution was rotating for 2 h at 4 °C. Afterwards, the beads were 
washed five times with lysis buffer (0.1 U/ml SUPERase inhibitors and 10 µg/ml yeast 
tRNA) and once with lysis buffer without additives. The beads were resuspended in 1 ml 
lysis buffer and divided to 200 µl (protein) and 800 µl (RNA) fractions. After pelletizing 
the beads with the magnet, the supernatant was discarded. For protein detection by 
Western Blot the beads were diluted in sample buffer and prepared for SDS-PAGE. From 
the other part of the beads RNA was extracted by use of the mirVanaTM Isolation Kit. 
RNA was eluted in 70 µl nuclease-free water followed by digestion of DNA by treatment 
with Turbo DNase according to the manufacturer’s protocol. After denaturation of the 
DNase for 10 min at 75 °C in the presence of 15 mM EDTA, RNA samples were kept on 
ice. For detection of specific mRNAs, cDNA was synthesized and RT-qPCR was 
performed (chapter 2.3.9). 
2.5  Immunocytochemistry (ICC) 
For microscopic analysis, cultured hippocampal neurons were fixed in 500 µl 4% 
paraformaldehyde/sucrose in DPBS for 15 min at RT. Subsequently, the cells were 
washed four times in 500 µl DPBS (2x 30 sec, 2x 5 min). For the analysis of dendritic 
spines and dendritic growth, the GFP expressing cells were mounted on microscope slides 
in Aqua-Poly/Mount. For immunocytochemistry the coverslips were transferred to a wet 
chamber. Primary and secondary antibodies were diluted in GDB (gelatine detergent 
buffer). The cells were incubated with the primary antibody for 1 h at RT in the dark. 
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After four wash steps with DPBS (1x 30 sec, 3x 5 min) the secondary antibody was 
applied for 1 h at RT protected from light. After three further wash steps with DPBS, 
Hoechst was incubated at 1:5000 in DPBS for 5 min. After all, the cells were mounted as 
described above (chapter 2.5).  
2.6  Microscopic analysis 
All microscopic images were taken with a Confocal Laser Scanning microscope. The 
presented immunocytochemistry images are the maximum projections of 2 - 4 confocal 
stacks with a z-distance of 0.5 – 1 µm. The measurements of average signal intensity and 
x-y-distance as well as further image processing were carried out with the ImageJ 
software. 
2.7  Spine assay 
For dendritic spine analysis, hippocampal neurons (13 DIV) were co-transfected with 200 
ng pEGFP-Amp, 5 ng of shRNA expressing pSuper construct and miR-134 duplex RNA. 
After 6 days (19 DIV) the cells were prepared for confocal imaging (chapter 2.5). 
Confocal z-stack images were taken with a 63x objective (7 z-stacks at 0.4 µm interval) 
and projected to a single plane image. The individual spine size was quantified by its 
mean grey value in a 2.2 µm2-circle using ImageJ software. More than 100 spines per cell 
were measured and normalized to the cell’s mean grey values. Spines from three 
independent experiments were measured. The imaging and analysis were carried out 
blinded to the experimental conditions. The spine assay was performed by Anna 
Tsankova under supervision of Peter Störchel. 
2.8  Sholl analysis 
For the determination of dendritic complexity by Sholl analysis, pyramidal neurons (12 
DIV) expressing GFP were imaged by fluorescence microscopy. The images were layered 
with a pattern of concentric circles with increasing radii, centered to the cell body (8 
circles with distances from soma between 25 – 200 µm). The dendritic outgrowth was 
determined by quantification of intersections between dendrites and each circle. The sum 
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of all dendrite intersections at each distance represents the total number of intersections. 
Per condition 10 to 12 cells were analyzed.  
2.9  Statistical analysis 
Statistical analysis for pairwise comparison was carried out by two-tailed, unpaired 
Student’s t-test. For multiple conditions, one-way Anova test (http://vassarstats.net/) was 
applied with Tukey HSD post-test comparing single conditions pairwise. Significance 
was set at p < 0.05. 
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3  Results 
3.1  Background – RNAi-based screen 
Previously, a large-scale RNAi-based screen in primary mouse cortical neuron cultures 
was performed in our laboratory to identify novel neuronal RBPs that modulate miRNA 
activity (Gabriele Siegel, PhD thesis, 2011). The study was based on the idea that the 
knockdown of crucial effector proteins should relieve the miRNA-mediated repression of 
translation that can be monitored by a luciferase reporter assay. The luciferase reporter 
construct contained downstream of the luciferase coding sequence the 3‘UTR of the gene 
Ube3a which is responsive to the neuronal miRNA miR-134 (Valluy et al. 2015). A 
subset of 286 RBPs that are expressed in the postnatal mouse cortex were chosen as 
candidate proteins (McKee et al. 2005). In the screening experiment each of the 
candidates was individually knocked down by transfection of synthetic siRNAs. 
Specifically, three different siRNAs for each RBP were separately co-transfected with the 
Ube3a luciferase reporter and miR-134-duplex RNA into primary mouse cortical neurons 
(5 days in vitro (DIV)). After three days the luciferase activity was measured (Figure 5 
A). 
Transfection of miR-134 duplex RNA led to an about 40% repression of the Ube3a-
luciferase reporter expression. In the case that an RBP was required for the inhibitory 
function of miR-134, we expected that the reporter repression was relieved in the presence 
of the respective siRNAs. Candidates were considered as positive hits if at least two out 
of three siRNAs could relieve the reporter repression by at least 50%. Using this criteria, 
12 RBPs that are required for the function of miR-134 were identified in this study (Figure 
5 B). Among the positive hits were Tnrc6c and Ddx6, two proteins that are known to be 
directly associated with miRISC (Chu et al. 2006; Chen et al. 2009). This confirmed that 
the screen setup allowed the identification of miRISC-associated factors. Importantly, ten 
new candidates (Ewsr1, Fubp1, Lsm7, Ncoa3, Nova1, Nxf1, Nxt1, Rbm25, Rpl5 and 
U2af1) were detected that had not yet been described in the context of miRISC regulation 
(Figure 5 B). A miRNA-independent function in RNA metabolism was previously 
reported for most of these RBPs. For example, Nova1, U2af1 and Rbm25 are involved in 
the regulation of RNA splicing (Jensen et al. 2000; Mollet et al. 2006; Zhou et al. 2008) 
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while others influence mRNA translation (Rpl5) (Meskauskas et al. 2001) or mRNA 
decay (Lsm7) (Tharun et al. 2000). The RBPs Ewsr1, Fubp1 and Ncoa3 had been 
implicated in transcription, whereas Nxf1 and Nxt1 were shown to regulate the nuclear 
export of mRNA.  
 
 
Figure 5: Large scale RNAi-based screen in primary mouse neurons 
A) Schematic overview of the RNAi screen in mouse primary neurons performed by G. Siegel. Cortical 
Neurons (5 days in vitro (DIV)) were co-transfected with pGL3-Ube3a 3’UTR luciferase reporter, miR-
134 duplex RNA and one siRNA targeting individual RBPs. Three different siRNAs were used for every 
RBP. After three days of incubation luciferase activity was determined. B) List of a representative subset 
of genes that were tested in the screen. The dashed line designates “known genes” that are involved in the 
regulation of miRNA activity. Thick line marks candidate genes that relieved reporter repression by at least 
50% with at least two out of three tested siRNAs. Values represent the relief of miRNA-mediated repression 
after siRNA treatment, obtained from three independent experiments. 
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3.2  Validation of RNAi screen results 
For the validation of the RNAi-based screen results (Siegel, 2011) I performed a 
secondary screen using only candidates that were classified as positive hits in the first 
study. To exclude false positives, the experimental setup was modified in the following 
points.  
First, I used an improved luciferase reporter system that should reduce potential non-
specific siRNA effects. The Ube3a 3’UTR was cloned downstream of the firefly coding 
sequence of the pGL4 plasmid (UBE3A-luc). Compared to the previously used pGL3 
vector, pGL4 contains less regulatory elements in the vector backbone. Thus, it minimizes 
the possibility of non-specific siRNA effects caused by factors that can potentially 
interact with regulatory elements in the vector. The UBE3A-luc reporter was co-
transfected with the miR-134 duplex RNA and the siRNAs for specific RBPs individually 
into immature rat cortical neurons (5 DIV). Furthermore, a condition was included where 
the reporter was co-transfected with the siRNA in the absence of miR-134 duplex. This 
condition should control for possible non-specific effects on luciferase mRNA translation 
caused by the siRNAs.  As a further control, an empty luciferase vector lacking 3’UTR 
sequence was co-transfected with the siRNA in the presence or absence of miR-134 
duplex. In the secondary screen only nine out of the 12 positive candidates (Nova1, 
Ncoa3, Ewsr1, Tnrc6c, Rpl5, Nxt1, Rbm25, U2af1, and Nxf1) were tested. Since the 
secondary screen was performed in rat, an siRNA was selected for each candidate that 
targets a sequence conserved between rat and mouse genomes and showed high efficacy 
in the primary screen. Lsm7 and Fubp1 were excluded, as none of the respective siRNAs 
was conserved between rat and mouse. Furthermore, Ddx6 was not included in the 
secondary screen since it was already shown to be involved in the regulation of miRNA 
activity (Chu et al. 2006). The known miRISC protein Tnrc6c was used as positive and a 
scrambled siRNA nucleotide (control siRNA) as a negative control in the screen. 
Luciferase activity was measured three days after transfection (8 DIV) and the experiment 
was performed three times.  
The results are presented as ratio between the condition that contains the miR-134 duplex 
RNA (“+miR”) and the condition without the miR-134 duplex RNA (“-miR”). In the 
basal condition where no siRNA was co-transfected as well as in the condition with 
control siRNA the ratio of “+miR” to “-miR” was about 0.5 (0.53 ± 0.05 (basal); 0.51 ± 
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0.05 (control siRNA)) (Figure 6 A). This reflects a nearly 50% downregulation of the 
UBE3A-luc reporter expression mediated by miR-134 overexpression. Compared to 
control siRNA (0.51 ± 0.05) the downregulation was significantly relieved when siRNAs 
against Nova1 (0.87 ± 0.20), Ncoa3 (0.84 ± 0.16), Ewsr1 (0.69 ± 0.08) and Tnrc6c (0.73 
± 0.14) were co-transfected. This suggests that Nova1, Ncoa3 and Ewsr1 are partially 
required for the repressive function of miR-134, in a comparable manner to Tnrc6c. 
Surprisingly the siRNAs against Rpl5 (0.62 ± 0.27), Nxt1 (0.52 ± 0.20), Rbm25 (0.51 ± 
0.07), U2af1 (0.49 ± 0.05) and Nxf1 (0.46 ± 0.03) did not significantly change the ratio 
“+miR” to “-miR” in the UBE3A-luc reporter. This suggests that knockdown of these 
RBPs might affect reporter gene expression independent of miR-134, for example due to 
a general role of these RBPs in mRNA translation. None of the siRNAs had a significant 
effect on the empty luciferase vector demonstrating that the effects of the siRNAs were 
strictly dependent on the presence of 3’UTR regulatory sequences (Figure 6 B).  
Among all candidates, the knockdown of Nova1 had the strongest activating effect on 
reporter gene expression. We therefore decided to study this RBP in more detail. The 
focus of this thesis was to characterize the role of Nova1 in the regulation of miRNA 
function and to understand the molecular mechanism whereby Nova1 knockdown impairs 
miRNA mediated inhibition of target mRNAs.  
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Figure 6: Luciferase reporter assay for the validation of positive hits using RNAi  
A) The pGL4-Ube3a-3’UTR luciferase reporter (UBE3A-luc) was co-transfected with miR-134 duplex 
RNA and one of the indicated siRNAs into rat cortical neurons at 5 DIV. Numbers of siRNAs refer to their 
original designation in the first screen. Plotted are normalized luciferase values as ratio of a condition with 
miR-134 duplex (“+miR”) to a condition without miR-134 duplex (“-miR”). Values are the average from 
three independent experiments ± standard deviation. *, p < 0.05 (unpaired Student’s t-test compared to 
control siRNA). B) An empty pGL4 plasmid was co-transfected together with miR-134 duplex RNA and 
one of the indicated siRNAs into rat cortical neurons at 5 DIV. Values are plotted as in (A). *, p < 0.05 
(unpaired Students t-test compared to control siRNA) 
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3.3  Expression analysis of Nova1 in primary neuronal cultures 
The endogenous expression of Nova1 protein was examined in cultured neurons using 
Western blot analysis and immunocytochemistry. First, protein lysates of rat hippocampal 
and cortical neurons were prepared at five different time points ranging from 7 DIV to 17 
DIV (hippocampus) or 5 DIV to 14 DIV (cortex). As shown in figure 7 A and B, Nova1 
was detected at all time points in both cell types, suggesting that it is expressed throughout 
the in vitro neuronal development. Expression of β-actin in the same lysates served as a 
loading control. 
In the next step, the subcellular localization of Nova1 protein was analyzed in more detail 
by immunocytochemistry (ICC) of hippocampal neurons (14 DIV) with an anti-Nova1 
antibody. The neuronal cell morphology was visualized by staining for the microtubule -
associated protein 2 (MAP2, green). The nuclei were stained with Hoechst dye (blue). 
Nova1 signal, shown in red, was observed in the cytoplasm and nucleus (Figure 7 C). The 
majority of cytoplasmic Nova1 was detected as granules surrounding the nucleus. Few 
Nova1 positive granules were also observed in the proximal parts of dendrites (arrows 
Figure 7 D).  
The subcellular localization of Nova1 assessed by ICC could be confirmed by a Western 
blot analysis of cytoplasmic and nuclear fractions prepared from rat cortical  neurons. 
Nova1 was detected in both fractions, with a more prominent expression in the nuclear 
fraction (Figure 7 E). Western Blots for α -tubulin and HDAC2 (Histone Deacetylase 2) 
confirmed the proper separation of cytoplasmic and nuclear fractions in this experiment.  
In conclusion, Nova1 protein is expressed in both the nucleus and cytoplasm of 
hippocampal neurons during the neuronal development between 7 and 14 DIV. 
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Figure 7: Expression of Nova1 in primary rat neurons in culture 
A), B) Western blot analysis of whole-cell protein lysates prepared from hippocampal (HC) (A) or cortical 
(CTX) (B) neuronal cultures at the indicated days in vitro (DIV). β-actin was used as a loading control. C), 
D) Immunocytochemistry analysis of Nova1 expression in hippocampal culture at 14 DIV. C) Signal of 
Nova1-specific antibody is pictured in red. The neuronal cell was visualized by a Map2 staining (green). 
Nuclei were stained with Hoechst (blue). D) Magnification of the insert depicted in (C) shows Nova1 signal 
in grayscale and nuclear and cellular outlines in yellow. Scale bar = 10 µm. E) Western blot analysis of 
Nova1 of whole cell lysates (input) and cytoplasmic (cyt) or nuclear (nuc) fractions obtained from FUDR-
treated rat hippocampal neurons at 7 DIV. α-tubulin was used as cytoplasmic marker. HDAC2 was used as 
nuclear marker. The fractionation experiment was performed in contribution with Peter Störchel. 
3.4  Nova1 is required for the repressive function of miRNAs 
3.4.1  Nova1 knockdown impairs miR-138 repressive activity in young cortical 
neurons 
To characterize the specific role of Nova1 in the regulation of miRNAs it was of interest 
to investigate whether Nova1 is required for the repressive function of other miRNAs 
apart from miR-134. To address this point, I examined the activity of the neuronal miRNA 
miR-138 in the context of Nova1 knockdown using luciferase reporter gene assays. 
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Luciferase assay was carried out using the miR-138 responsive APT1 3’UTR luciferase 
construct in the pGL4 vector (APT1-luc). APT1 (Acyl-Protein-Thioesterase-1) is 
encoded by the LYPLA1 gene which contains a binding site for miR-138 in the 3’UTR 
(Siegel et al. 2009).  
Analogous to the secondary screen (chapter 3.2) the luciferase reporter was co-transfected 
into young rat cortical neurons (5 DIV) together with the miR-138 duplex RNA and either 
control siRNA or the siRNAs targeting Nova1 or Ewsr1, respectively. The luciferase 
activity was measured three days after transfection.  
The results are presented as ratio between the condition with miR-138 duplex RNA 
(“+miR”) and the condition without miR-138 duplex RNA (“-miR”) (Figure 8). 
Overexpression of miR-138 only (basal) led to a significant repression of the APT1 
luciferase reporter (0.34 ± 0.07). The knockdown of Nova1 caused a significant relief of 
the repression (0.76 ± 0.26) whereas the knockdown of Ewsr1 had no effect on the 
reporter expression (0.32 ± 0.07). This result suggests that Nova1 knockdown interferes 
with miR-138 mediated repression of reporter gene expression similar to miR-134 
function. In conclusion, this suggests that Nova1 regulates the activity of several neuronal 
miRNAs, whereas Ewsr1 might be more specific for the regulation of miR-134.  
 
Figure 8: Luciferase reporter assay of APT1-luc in cortical neurons overexpressing miR-138 
pGL4-APT1 3’UTR (APT1-luc) was co-transfected into rat cortical neurons at 5 days in vitro (DIV) with 
indicated siRNAs in the presence (“+miR”) or absence (“-miR”) of miR-138 duplex RNA. Values represent 
ratio of the two conditions (“+miR”/”-miR”) and are the average from three independent experiments ± 
standard deviation. *, p < 0.05 (unpaired Student’s t-test compared to control siRNA). 
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3.4.2  Nova1 is required for the repressive activity of endogenous miR-134 and 
miR-138 
Nova1 mediates the repressive activity of overexpressed miR-134 and miR-138, and 
Nova1 may also be necessary for the activity of endogenously expressed miRNAs in 
neurons. In order to answer this question, luciferase assays were performed in rat cortical 
neurons at 14 DIV, as miRNAs are abundantly expressed at this developmental stage  
(Schratt et al. 2006; Siegel et al. 2009). The 3’UTR luciferase reporters, APT1-luc and 
UBE3A-luc, were transfected into cortical neurons two days earlier (12 DIV). 
Knockdown of Nova1 was achieved with an shRNA expression vector (pSuper) that gives 
rise to the previously used Nova1 siRNA-3 (chapter 3.2 and 3.4.1). To validate the 
specificity of the Nova1 shRNA a rescue experiment was performed, expressing an 
shRNA-resistant GFP-Nova1-fusion protein (GFP-Nova1R) in the context of the Nova1 
shRNA. The results are presented as relative luciferase activity (RLA) values that were 
normalized to basal condition, expressing the reporter plasmid APT1-luc or UBE3A-luc 
only. 
The knockdown of Nova1 significantly increased the expression of APT1-luc (1.40 ± 
0.18) and Ube3a-luc (1.29 ± 0.18) compared to the control shRNA (0.78 ± 0.15 (APT1-
luc); 0.83 ± 0.06 (Ube3a-luc)) (Figure 9 A, B). This effect is in agreement with the Nova1 
siRNA-mediated relief of repression of the luciferase reporter (Figure 6 A and 8). 
Reintroduction of Nova1 by co-transfection of the shRNA-resistant GFP- Nova1R 
construct partially rescued the effect of the Nova1 shRNA, since APT1-luc (1.09 ± 0.10) 
and UBE3A-luc (1.00 ± 0.27) expression was significantly decreased. In contrast, 
expressing GFP only (1.41 ± 0.09 (APT1-luc); 1.27 ± 0.15 (Ube3a-luc)) did not alter the 
effect of the Nova1 shRNA which confirms that changes in Nova1 protein levels are 
responsible for the observed differences of luciferase expression. In sum, these results 
suggest that Nova1 is required for the repression of reporter genes that are regulated by 
the endogenous miR-134 and miR-138 in rat cortical neurons. In addition, overexpression 
of GPF-Nova1 significantly decreased the expression of the APT1-luc as well as the 
UBE3A-luc reporter compared to the GFP control (Figure 9 C and D). These results 
suggest that Nova1 is both necessary and sufficient to repress Ube3a and APT1 
expression in neurons.  
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Figure 9: Luciferase reporter assays of APT1-luc and Ube3a-luc in mature cortical neurons  
A-D) Luciferase assay in rat cortical neurons (14 DIV) that had been transfected with pGL4-APT1-3’UTR 
(APT1-luc) or pGL4-UBE3A-3’UTR (UBE3A-luc). In A) and B) pSuper vectors expressing either Nova1 
shRNA or control shRNA and a shRNA resistant GFP-Nova1 fusion construct or a GFP control vector were 
co-transfected. In C) and D) a GFP-Nova1 fusion construct or GFP control vector were co-transfected. 
Relative luciferase activity (RLA) represents the ratio of firefly reporter to renilla control reporter normal-
ized to a basal condition without shRNA expressing vector (A, B) or 3’UTR luciferase reporter only (C, 
D). Values are the average from three independent experiments ± standard deviation. *, p < 0.05 (unpaired 
Student’s t-test compared to control shRNA or as indicated).  
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3.4.3  Nova1 knockdown interferes with miR-134-, miR-124- and let-7-dependent 
repression of luciferase reporter genes 
In order to verify that the repressive function of Nova1 indeed dependents on miRNA 
activity a set of luciferase reporters with mutated miRNA binding sites was generated by 
site directed mutagenesis. The set consists of luciferase reporters containing 3’UTRs of 
Limk1 (LIMK1-luc), a target gene of miR-134; Iqgap1 (IQGAP1-luc), a target gene of 
miR-124; as well as lin41 (LIN41-luc) and HMGA2 (HMGA2-luc), two target genes of 
the miRNA let-7. In addition, mutant reporters with disrupted miRNA binding sites were 
generated for all mentioned 3’UTRs. The constructs were individually co-transfected into 
mature cortical neurons at 12 DIV together with the Nova1 shRNA or control shRNA 
vector. The results are displayed as relative luciferase activity (RLA), normalized to a 
basal condition which contains the respective reporter plasmid without shRNA expressing 
vector. 
The LIMK1 wildtype reporter (LIMK1 WT) exhibits a significant increase of luciferase 
activity under Nova1 knockdown condition (1.63 ± 0.14) (Figure 10 A) similar to the 
effects that were observed for APT1-luc and UBE3A-luc (Figure 9). Activity of LIMK 
WT was significantly higher compared to LIMK1 mut (1.34 ± 0.10) upon Nova1 
knockdown (Figure 10 A). Similar observations were made for the reporter IQGAP1-luc. 
Under Nova1 shRNA condition the expression of IQGAP1 WT (1.63 ± 0.13) was 
significantly increased compared to IQGAP1 mutant (1.23 ± 0.03) (Figure 10 B). 
Likewise, the luciferase activity of the let-7 target gene lin41 (Vella et al. 2004) (LIN41-
luc) revealed a significant difference between wildtype (LIN41 WT) and mutant (LIN41 
mut) specifically under Nova1 knockdown conditions (1.84 ± 0.26 (WT); 1.24 ± 0.15 
(mut)) (Figure 10 C). In contrast the wildtype (HMGA2 WT) and mutant (HMGA2 mut) 
reporter of another let-7 target gene, HMGA2 (Nishino et al. 2008), were both 
significantly upregulated to a similar extend under Nova1 knockdown condition (1.46 ± 
0.20 (WT); 1.35 ± 0.14 (mut)) compared to the shRNA control condition (Figure 10 D). 
Taken together these results suggest that Nova1 represses the LIMK1-, IQGAP1- and 
LIN41- luciferase reporters in a manner dependent on the validated miRNA binding sites. 
In contrast, Nova1 regulation of HMGA2 appears to be let-7-independent and may 
therefore depend on other miRNA binding sites present in the HMGA2 3’UTR.  
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Figure 10: Luciferase reporter assays of wildtype and mutated miRNA binding site reporter in 
mature cortical neurons 
A-D) Luciferase assay in rat cortical neurons (14 DIV) that had been transfected with the indicated 3’UTR 
luciferase constructs at 12 DIV together with pSuper vectors expressing either Nova1 shRNA or control 
shRNA. Relative luciferase activity (RLA) represents the ratio of firefly reporter to renilla control reporter 
normalized to a basal condition without shRNA expression vector. Values represent averages from at least 
three independent experiments ± standard deviation. *, p < 0.05 **, p < 0.01 (unpaired Student’s t-test 
compared to control shRNA or as indicated by bars).  
3.4.4  Nova1-dependent regulation of miRNA activity is independent of the 3’UTR 
context 
The previous results demonstrate that Nova1 acts in a miRNA-dependent manner on the 
repression of numerous target gene reporters. Next, I analyzed whether the presence of a 
miRNA binding site alone is sufficient for the regulatory function of Nova1. In order to 
examine isolated miRNA-binding sites, I performed luciferase assays with a miR-138 
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specific sponge reporter. The miR-138 sponge construct (138sponge luc) harbors six 
consecutive binding sites for miR-138 downstream of the firefly coding sequence, but 
lacks other 3’UTR sequences (Figure 11 A). This sponge construct provides a suitable 
tool to examine whether regulatory sequence elements outside miRNA binding sites are 
required for the function of Nova1. A construct in which the miR-138 binding site array 
was cloned in reverse orientation (ctrl sponge) served as a control. The expression of 
138sponge luc was significantly increased under Nova1 shRNA condition (1.52 ± 0.18) 
compared to the control shRNA condition (0.98 ± 0.12) (Figure 11 B). In contrast, the 
control sponge reporter expression did not change significantly upon Nova1 knockdown 
(1.11 ± 0.18) compared to the control shRNA (0.93 ± 0.03). This result indicates that 
Nova1 can act as a regulator of miRNA function independently of the 3’UTR sequence 
context. 
 
Figure 11: Luciferase reporter assay of miR-138 sponge reporter in mature cortical neurons 
A) Illustration of the miR-138 sponge luciferase reporter construct (138sponge luc). Six sequential miR-
138 binding sites are located downstream of the luciferase coding sequence in place of an entire 3’UTR 
sequence. B) Luciferase assay in rat cortical neurons (14 DIV) transfected with the miR-138 sponge 
luciferase construct (138 sponge) or a control containing the reversed sequence of the 138 sponge (ctrl 
sponge) together with pSuper vectors expressing either Nova1 shRNA or control shRNA. Relative 
luciferase activity (RLA) represents the ratio of firefly reporter to renilla control reporter normalized to a 
basal condition without shRNA expression vector. Values represent averages from at least three 
independent experiments ± standard deviation. *, p < 0.05 **, p < 0.01 (unpaired Student’s t-test).  
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3.4.5  Nova1 is required for miR-134 mediated repression of endogenous Limk1 
MiRNA-mediated mRNA repression usually leads to decreased protein expression. 
Consequently, it was of interest to study whether the observed regulation of artificial 
miRNA target gene reporters by Nova1 corresponds to alterations in the respective endog-
enous protein levels. In order to yield a high Nova1 knockdown efficiency in the neuronal 
culture, shRNAs were delivered via infection of rAAV particles. Therefore, whole cell 
lysates were obtained from cortical neurons at 14 DIV that had been infected with 
recombinant adeno-associated virus (rAAV) expressing Nova1 shRNA. Nova1 
knockdown efficiency was assessed by Western blot using lysates from rAAV-Nova1 
shRNA infected neurons. Nova1 levels were significantly reduced in Nova1 shRNA 
compared to control shRNA infected neurons (Figure 12 A).  
  
 
Figure 12: Western blot analysis upon rAAV-mediated Nova1 knockdown 
A) Western blot analysis of Nova1 and Limk1 protein in 14 DIV old cortical neurons that had been infected 
with rAAV expressing either Nova1 shRNA or control shRNA. β-Actin served as a loading control. Results 
of two independent experiments are shown. B) Quantification of Western blot signal intensity. Bars 
represent relative band intensities that were normalized to β-Actin of the two independent experiments 
shown in A.  
For the analysis of miRNA target gene expression, I focused on the miR-134 target Limk1 
which is an important regulator of spine morphogenesis in dendrites. Limk1 protein 
amounts were increased by a factor of 1.8 in lysates obtained from two independent 
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infections of neurons with Nova1 shRNA compared to control shRNA as visualized by 
band quantification and normalization (Figure 12). In conclusion, Nova1 is required for 
the repression of the endogenous miRNA target protein Limk1. This result is consistent 
with the observation that Nova1 knockdown significantly upregulates the expression of 
the Limk1 luciferase reporter in a miR-134 - dependent manner (Figure 10 A). 
3.5  Nova1 interaction studies 
3.5.1  Nova1 interacts with Ago in lysates obtained from the rat hippocampus 
The previous results imply that Nova1 regulates the repression of several miRNA targets 
irrespective of the 3’UTR context (Figure 10 and Figure 11). I therefore hypothesized that 
Nova1 could directly interact with miRISC proteins, rather than with the miRNA target 
mRNA. A co-Immunoprecipitation (co-IP) experiment was performed in hippocampal 
lysates, obtained from adult rat brain, to test a putative interaction between Nova1 and 
Ago, the major component of miRISC. Ago proteins were precipitated with a specific 
pan-Ago antibody and detected by Western blot (Figure 13 A). In the upper part of the 
figure a specific enrichment of Ago2 in the Ago IP compared to the IgG control can be 
observed. This demonstrates successful precipitation of Ago2 with the pan-Ago antibody. 
Ago2 was not detectable in the input lysate, probably due to a low solubilization of Ago2 
achieved with this lysis protocol. Importantly, a band migrating at the expected molecular 
weight of Nova1 could be specifically detected in the pan-Ago-IP fraction but not in the 
IgG control. This result suggests that Nova1 and Ago2 interact in the rat hippocampus. 
In conclusion, Nova1 represents a novel interactor of neuronal miRISC.  
Performing additional co-IP experiments, I investigated whether an association between 
Ago2 and Nova1 protein was dependent on the presence of RNA. For this purpose, lysates 
were treated with RNase before immunoprecipitation. The specific enrichment of Ago2 
in pan-Ago immunoprecipitates was again confirmed by Western blot as presented in the 
upper part of Figure 13 B. Similar to Figure 13 A, a band at the molecular size of Nova1 
was observed by anti-Nova1 Western blot in the pan-Ago IP in the presence of RNase. 
This result suggests that the interaction between Nova1 and Ago does not require the 
presence of intact RNA, which further implies that Nova1 and Ago reside within a protein 
complex. 
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Figure 13: Co-immunoprecipitation of Nova1 and Ago proteins  
A) Representative co-IP experiment in hippocampal lysates obtained from adult rat brain using a pan-Ago 
antibody. Upper part: Western blot using anti-Ago2 antibody exhibits specific precipitation of Ago2 in pan-
Ago IP. Lower part: Western blot using anti-Nova1 antibody exhibits specific co-precipitation of Nova1 
(52 kDa) and Ago proteins. *, non-identified cross-reactive proteins. Diagram at the bottom represents band 
intensity as percentage of input averaged over two independent experiments. B) Co-IP performed as in A) 
with additional RNAse treatment of lysates before co-IP experiment. 
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3.5.2  Validation of Nova1 / mRNA association by RNA immunoprecipitation 
To further validate a potential interaction between Nova1 and miRISC, I next investigated 
whether Nova1 is associated with miRNA target mRNAs. Therefore, endogenous Nova1 
protein was immunoprecipitated using a Nova1-specific antibody in hippocampal lysates 
obtained from adult rat brain. Protein and RNA extracts were prepared from these 
precipitates. The pulldown of Nova1 protein was confirmed by Western blot analysis 
(Figure 14 A). Nova1 was strongly enriched in the Nova1-IP fraction compared to the 
IgG control fraction. The presence of specific mRNAs in the Nova1 IP fraction was 
assessed by quantitative Real Time PCR (qPCR). The bar graph in Figure 14 B represents 
the relative amount of mRNAs in either IgG or Nova1 IP fraction compared to the input. 
Limk1 mRNA was highly enriched in the Nova1 IP compared to IgG control IP. Rgs4 
mRNA was previously shown to interact with Nova1 and served as a positive control 
(Licatalosi et al. 2008). Gapdh mRNA, which is not known to be Nova1-associated, was 
used as a negative control. Together, the results suggest that Nova1 is associated with 
endogenous miRNA target mRNAs, such as the miR-134 target Limk1 mRNA. Since 
Nova1 interacts with Ago proteins, this result is likely due to an indirect association of 
Nova1 with miRNA targets via miRISC. 
 
 
Figure 14: Nova1 RNA-immunoprecipitation in hippocampal lysates 
A) RNA-immunoprecipitation (RIP) in rat adult hippocampus using a Nova1 specific or an IgG control 
antibody. Specific IP of Nova1 was confirmed by Western blot analysis. *, non-identified cross-reactive 
proteins B) qPCR for the indicated transcripts in RIP samples. Bars represent the ratio of mRNA present in 
Nova1 or IgG control IPs compared to mRNA present in input averaged over three independent experiments 
± standard deviation. **, p < 0.01 (unpaired Student’s t-test).  
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3.5.3  Luciferase-based tethering assay of full length Nova1 protein 
Having shown that Nova1 associates with miRISC and miRNA target mRNAs, I further 
investigated the functional activity of Nova1 in the regulation of mRNA translation. I 
examined whether Nova1 can regulate gene expression independently of its ability to bind 
RNA by performing a luciferase-based tethering assay (Pillai et al. 2005). In this assay 
the protein of interest is recruited to the 3’UTR of a luciferase reporter through an 
artificial RNA protein interaction. This allows the experimental separation of protein 
function from its interaction with RNA. Here, Nova1 is fused to the lambda-phage N-
peptide that can directly bind to an RNA hairpin structure (5boxB) that is engineered 
downstream of the luciferase gene within the reporter vector. First the correct expression 
of the NHA-fusion constructs was validated by Western blot analysis of lysates obtained 
from HEK293 cells that were transfected with the respective vectors. A band at the 
expected size was detected for all constructs (Figure 15 A). Next, I performed luciferase 
experiments in rat cortical neurons and HEK293 cells using the indicated tethering assay 
constructs. When NHA-Nova1 was tethered to the reporter construct, the luciferase 
activity was significantly decreased (0.40 ± 0.08 (CTX); 0.40 ± 0.06 (HEK293)) 
compared to the NHA-GFP (0.88 ± 0.11) or NHA-Ncoa3 (0.95 ± 0.11) control conditions 
(Figure 15 B, C). Likewise tethering the miRISC protein Tnrc6c (NHA-Tnrc6c), which 
serves as a positive control, strongly reduced the reporter activity (0.20 ± 0.10 (CTX); 
0.09 ± 0.02 (HEK293)) compared to the control. Expression of the NHA domain alone 
had no effect on luciferase activity (1.22 ± 0.03) (Figure 15 B). This result shows that 
Nova1 is capable of repressing mRNA translation independently of its RNA binding 
capacity. It further indicates that Nova1 possesses an intrinsic repressive activity on 
mRNA translation, either directly or by recruiting additional translational repressors to 
the mRNA. 
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Figure 15: Tethering assay of Nova1 
A) Western blot analysis of lysates obtained from HEK293 cells that were transfected with the indicated 
NHA fusion constructs. Anti-HA antibody was used for detection of fusion proteins and β-actin served as 
a loading control. *, non-identified cross-reactive proteins B), C) Luciferase assay in 7 DIV old rat cortical 
neurons (B) and HEK293 cells (C) that had been transfected with the luciferase expression vector (RL-
5boxB) together with the indicated fusion constructs. Relative luciferase activity (RLA) represents the ratio 
of renilla reporter to firefly control reporter normalized to a condition expressing RL-5boxB only. Values 
are the average from at least three independent experiments ± standard deviation. ns, not significant *, p < 
0.05 **, p < 0.01 (unpaired Student’s t-test compared to RL-5boxB only or as indicated by bars).  
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3.5.4  Luciferase-based tethering assay of Nova1 deletion constructs 
The previous results revealed a repressive function of Nova1 in mRNA translation (Figure 
15). To narrow down the region which could facilitate its repressive activity, I generated 
two deletion mutants of Nova1 and analyzed them in a tethering assay. The two truncated 
Nova1 fusion proteins consist of either the first 236 amino acids of Nova1 (NHA-Nova1 
(1-236)) or of amino acid 237 to 506 (NHA-Nova1 (237-506)). First the subcellular 
localization of the deletion constructs was studied in cultured hippocampal neurons by 
immunocytochemistry using an anti-HA antibody. The construct expressing the N-
terminal part of Nova1 (NHA-Nova1 (1-236)) lacks the nuclear export signal (NES) and 
is therefore only present in the nucleus (Figure 16 A). In contrast, the construct expressing 
the C-terminal part of Nova1 (NHA-Nova1 (237-506)) that lacks the nuclear localization 
signal (NLS) was only detected in the cytosol (Figure 16 A). The expression of these 
proteins was further examined by Western blot analysis of lysates obtained from HEK293 
cells that were transfected with the two Nova1 deletion constructs. A signal at the 
estimated size of about 26 kDa was detected with the anti-HA antibody for both constructs 
(Figure 16 B). Next, the luciferase-based tethering assay was performed in rat cortical 
neurons using wildtype Nova1 protein and the Nova1 deletion mutants. In contrast to the 
Nova1 full-length protein (0.46 ± 0.10) none of the mutants were able to repress the 
luciferase reporter significantly when being tethered to the reporter plasmid (0.96 ± 0.09 
(NHA-Nova1(1-236)); 0.88 ± 0.35 (NHA-Nova1 (237-506))) (Figure 16 C). In 
conclusion, a combination of domains present in both the N- and C-terminus of Nova1 
appears to be required for the full repressive activity of Nova1.  
  RESULTS 
65 
 
 
Figure 16: Tethering assay of Nova1 deletion constructs 
A) Immunocytochemistry of indicated NHA-Nova1 deletion constructs transfected into cultured 
hippocampal neurons at 14 DIV. Fusion proteins were detected with an anti-HA antibody (green). Neuronal 
cells were visualized by Map2 staining (red). Nuclei were stained with Hoechst (blue). B) Western blot 
analysis of lysates obtained from HEK293 cells that were transfected with the indicated NHA fusion 
constructs. Anti-HA antibody was used for their detection C) Luciferase assay in 7 DIV old rat cortical 
neurons that had been transfected with the luciferase expression vector (RL-5boxB) together with the 
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indicated fusion constructs. Relative luciferase activity (RLA) represents the ratio of renilla reporter to 
firefly control reporter normalized to a condition without additional expression vector (“RL-5boxB only”). 
Values represent averages from three independent experiments ± standard deviation. **, p < 0.01 (unpaired 
Student’s t-test). 
3.6  The function of Nova1 in neuronal morphogenesis and signal 
transduction 
3.6.1  Nova1 is required for miR-134 mediated spine morphogenesis 
MiR-134 regulates dendritic spine size by repressing the translation of Limk1 mRNA, 
which encodes an actin regulatory protein kinase that promotes spine growth. It was 
shown that the spine size of hippocampal neurons was significantly reduced upon 
overexpression of miR-134 (Schratt et al. 2006). In previous experiments of this thesis it 
was observed that Nova1 is interfering with the miR-134 mediated repression of the 
Limk1 expression in luciferase reporter gene assays and that Nova1 furthermore 
associates with Limk1 mRNA. To test whether Nova1 function is required for miR-134 
mediated spine size reduction a spine assay was performed in mature hippocampal 
neurons. The spine assay was performed in collaboration with Peter Störchel (Störchel 
and Thümmler et al. 2015). A Nova1 shRNA expressing pSuper vector was co-
transfected with GFP into cultured hippocampal neurons at 13 DIV in the presence or 
absence of miR-134 duplex RNA. The cells were fixed after six days and the spines were 
visualized by confocal microscopy followed by the quantitative measurement of spine 
volume based on GFP filling (chapter 2.7). In order to reduce variability, only spines  
along the basal dendrites were considered. Overexpression of miR-134 led to a significant 
reduction of the spine size in hippocampal neurons (Figure 17). This result is in 
accordance with the reported findings in Schratt et al in 2006. The miR-134 induced spine 
size reduction was abolished after Nova1 knockdown by shRNA. However, spine size 
was reduced in a condition with an empty vector control. This shows that Nova1 is 
required for the miR-134 mediated spine size reduction in hippocampal neurons and that 
Nova1 regulation of miRNA activity is functionally relevant for the morphology of 
synapses. 
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Figure 17: Spine assay in hippocampal neurons upon Nova1 knockdown and miR-134 
overexpression 
A) Spine analysis of hippocampal neurons (19 DIV) that were transfected at 13 DIV with Nova1 shRNA 
expressing pSuper vector or an empty control vector together with pEGFP in the presence or absence of 
miR-134 duplex RNA (+miR-134). Shown are representative sections of dendrites with dendritic spines. 
Scale bar = 5 µm B) Bars represent quantified relative spine volume normalized to a basal condition without 
shRNA expression vector. Values represent averages from three independent experiments each including 
6 cells per condition ± standard deviation. ns, not significant *, p < 0.05 (unpaired Student’s t-test). The 
spine assay was carried out by Anna Tsankova under supervision of Peter Störchel. 
3.6.2  The role of Nova1 in dendrite outgrowth 
It was previously shown from our group that besides controlling neuronal spine growth 
miR-134 is involved in the activity-dependent regulation of dendrite outgrowth. In this 
context, miR-134 inhibits the translation of the translational repressor Pumilio2 (Pum2) 
that results in an increase of dendritic outgrowth of hippocampal neurons (Fiore et al. 
2009). To test whether Nova1 plays a role in the regulation of dendritogenesis in 
hippocampal neurons, dendritic complexity was assessed upon Nova1 knockdown under 
basal conditions. The analysis of dendritic outgrowth was performed in collaboration with 
Gabriele Siegel (Störchel and Thümmler et al. 2015). Cultured hippocampal neurons 
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were transfected with a Nova1 shRNA expression vector together with pEGFP and 
prepared for confocal microscopy at DIV10. The dendritic outgrowth of the cells was 
determined using the Sholl method. Microscopic images of single neurons were 
superimposed with concentric circles of different radii around the cell body. The 
intersections of dendrites with the circles where quantified at each distance. The dendritic 
complexity was not affected under Nova1 knockdown conditions in areas close to the cell 
body (25-100 µm) compared to the shRNA control (Figure 18 A). In contrast, at circles 
with more distance to the cell body (125-175 µm) the dendritic growth was significantly 
reduced upon Nova1 knockdown. However, the summation of all intersections with every 
circle showed no significant difference of dendritic outgrowth in the Nova1 knockdown 
compared to the control shRNA (Figure 18 B). This suggests that Nova1 has no major 
functional relevance in the regulation of dendritic outgrowth under basal conditions. 
However, Nova1 is specifically required for the proper development of dendrites at large 
distances from the neuronal soma, possibly via regulation of dendritic miRNA activity. 
 
 
Figure 18: Dendritic outgrowth after Nova1 knockdown 
A) Dendritic outgrowth of cultured hippocampal neurons (10 DIV) that were transfected at 4 DIV with 
Nova1 shRNA expressing pSuper vector or an empty control vector together with pEGFP was determined 
by Sholl analysis. B) Bars represent the accumulated number of intersections from data in A and normalized 
to a basal condition without shRNA expression vector. Values represent averages from three independent 
experiments ± standard deviation. *, p < 0.05 (unpaired Student’s t-test). Data was obtained by Gabriele 
Siegel. 
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3.6.3  The function of Nova1 in BDNF signaling 
I found that Nova1 is required for miR-134 mediated spine shrinkage in hippocampal 
neurons (chapter 3.6.1). It was previously shown that the inhibitory effect of miR-134 on 
spine growth can be reversed by the application of brain-derived neurotrophic factor 
(BDNF) (Schratt et al. 2006). This prompted me to analyze the function of Nova1 in 
BDNF-regulated Limk1 mRNA translation using a Limk1 3’UTR luciferase reporter 
vector containing a destabilized firefly open reading frame (LIMK1-lucPEST). The 
luciferase protein encoded by this vector has a higher turnover rate than the conventional 
luciferase protein. Therefore, this system can better monitor stimulus-dependent 
alterations in gene expression compared to the conventional, very stable luciferase 
reporter system.  Under normal growth conditions, Nova1 knockdown caused an about 
2-fold increase of the luciferase expression (2.16 ± 0.64) compared to the control shRNA 
condition (1.08 ± 0.42) (Figure 19 A). 5 h BDNF treatment of neurons induced a 
significant upregulation of the reporter expression in the condition without shRNA 
expression construct (“no shRNA”) (1.00 (basal); 2.37 ± 0.41 (BDNF)). Under Nova1 
knockdown this BDNF-mediated increase was impaired (2.16 ± 0.64 (basal); 2.65 ± 0.36 
(BDNF)) compared to control shRNA condition (1.08 ± 0.42 (basal); 2.03 ± 0.35 
(BDNF)), suggesting that Nova1 is required for the BDNF mediated upregulation of the 
Limk1 reporter (Figure 19 A). Both BDNF application and Nova1-knockdown induced 
an upregulation of the Limk1-lucPEST which raises the possibility that Nova1 is a 
downstream effector of BDNF signaling. For this reason, Nova1 protein levels were 
examined in cortical neurons after BDNF treatment for different durations. The Western 
blot analysis for Nova1 after incubation with BDNF for different timepoints between 5 
min to 5 h however did not reveal significant changes of total Nova1 protein levels (Figure 
19 B). Taken together, these results suggest that Nova1 is involved in the dynamic control 
of Limk1 mRNA translation in response to BDNF signaling. Since BDNF did not affect 
Nova1 protein levels, the inactivation of Nova1 by BDNF might be caused by post-
translational modifications. 
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Figure 19: Luciferase assay and Western blot analysis upon BDNF treatment 
A) Luciferase assay in rat cortical neurons (7 DIV) that had been transfected at 5 DIV with a Limk1 3’UTR 
luciferase construct that contains a destabilized firefly ORF (lucPEST) together with pSuper vectors 
expressing either Nova1 shRNA or control shRNA. Prior luciferase measurement neurons were treated with 
BDNF (100 ng/ml) or kept untreated (“basal”) for 5 h. Relative luciferase activity (RLA) represents the 
ratio of firefly reporter to renilla control reporter normalized to a condition without shRNA expressing 
vector (“no shRNA”) and no BDNF stimulation. Values represent averages from at least three independent 
experiments ± standard deviation. ns, not significant *, p < 0.05 (unpaired Student’s t-test). B) Western blot 
analysis of lysates obtained from cortical neurons at 14 DIV treated with BDNF for indicated time or mock-
treated (basal). Anti-pan Nova antibody was used for detection of Nova1. β-actin served as a loading 
control. *, non-identified cross-reactive proteins. 
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4  Discussion 
MiRNAs are important regulators of mRNA translation in the nervous system and control 
important aspects of brain development, neuronal differentiation and synaptic plasticity 
(Aksoy-Aksel et al. 2014; Bicker et al. 2014). Previous studies showed that specific 
miRNAs, such as miR134, regulate the local translation of mRNAs at the synapse thereby 
controlling activity-dependent changes in synaptic strength (Schratt et al. 2006). The 
miRNA-induced silencing complex (miRISC) plays a crucial role in the miRNA-
mediated repression of mRNA translation (Fabian et al. 2012). For non-neuronal cells it 
is known that the activity of miRNAs is modulated by RNA-binding proteins (RBPs) that 
are not core components of miRISC (Krol et al. 2010b). However, miRNA modulating 
functions of RBPs in neurons are poorly understood. Based on a large-scale RNAi screen, 
I identified Nova1 as a novel neuron-specific modulator of miRNA function, with 
potential implications for the regulation of dendritic protein synthesis and synaptic 
plasticity. 
4.1  RNAi based screen in neurons 
In this project I validated an initial screening approach from our lab that represents the 
first reported large scale functional RNAi screen in primary neurons (Störchel and 
Thümmler et al. 2015). Among the positive hits of the screen were the two known 
miRISC factors Tnrc6c and Ddx6, which demonstrates that the screen setup enables the 
identification of established factors in miRNA function. Tnrc6c and Ddx6 are direct Ago-
interacting proteins that play essential roles in miRNA-mediated gene silencing (Chu et 
al. 2006; Pfaff et al. 2013). Importantly, three new factors (Nova1, Ncoa3 and Ewsr1) 
that are required for miRNA function emerged from the whole screening study (Figure 
6). So far, these proteins were neither associated with miRNA function nor found in other 
published studies that described miRNA regulatory proteins in non-neuronal cell systems 
(Eulalio et al. 2008). This suggests that neuronal miRNA activity is subject to regulation 
by a specific subset of RNA-binding proteins. 
The knockdown of the other RBPs that were classified as positive candidates in the large-
scale screen did not reveal any significant relief of reporter repression in a more specific 
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secondary screen. These proteins therefore might play a more general role in the regula-
tion of mRNA translation not directly related to miRNA-dependent repression. 
4.2  Nova1 is expressed in the nucleus and cytoplasm of neurons 
Nova proteins (Nova1 and Nova2) were first characterized as onconeural antigens in the 
human motor disorder paraneoplastic opsoclonus myoclonus ataxia (POMA) that occurs 
in breast or lung cancer patients (Buckanovich et al. 1993). Nova1 and Nova2 are related 
proteins that have 75% sequence homology and are particularly conserved within their 
KH domains (Lewis et al. 1999). Both Nova genes were among the 286 RBPs that were 
analyzed in the initial screen. However, in contrast to Nova1, Nova2 knockdown did not 
significantly alter miR-134 mediated reporter repression and for this reason was not 
considered for follow-up experiments (Siegel, 2011). This finding indicates specific, non-
redundant functions of Nova proteins in post-transcriptional gene regulation. 
Nova1 was shown to regulate alternative splicing in neurons and to target a set of mRNA 
transcripts that encode components of inhibitory synapses (Jensen et al. 2000; Ule et al. 
2003). The expression of Nova1, which is restricted to subcortical parts of the central 
nervous system, was shown to be largely confined to the nuclear compartment 
(Buckanovich et al. 1996; Buckanovich et al. 1997). However, more recently significant 
amounts of Nova1 protein were detected in the cytoplasm of mouse brain cells. It was 
reported that 50% of cellular Nova1 protein localizes to the soma-dendritic compartment. 
Consistent with this localization pattern, Nova1 contains both a nuclear export (NES) and 
nuclear localization signal (NLS) that allow the protein to shuttle between the nucleus 
and cytoplasm (Racca et al. 2010).  
The results obtained within this thesis further support nucleo-cytoplasmic shuttling of 
Nova1. First, the results from Western Blot analysis show that Nova1 protein is 
endogenously expressed throughout the in vitro development of hippocampal and cortical 
neurons between 7 and 14 DIV (Figure 7 A, B). Furthermore, the protein was detected by 
immunocytochemistry in the nucleus and in the cytoplasm of hippocampal neurons. The 
majority of cytoplasmic Nova1 was observed in a granular pattern surrounding the nu-
cleus (Figure 7 C, D). Comparing the relative amount of protein in both cell compartments 
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by Western blotting, I observed a prominent expression of Nova1 in the nucleus (Figure 
7 E).  
Similarly, the study from Racca et al. detected the majority (~60%) of Nova1 protein in 
the nucleus compared to the cytoplasm when it was normalized to total protein amount 
which was done in my experiment as well. On the one hand, this result is in agreement 
with the function of Nova1 as a nuclear splicing factor. On the other hand, these 
observations suggest an alternative cytosolic function of Nova1. In fact, the same study 
reported that Nova co-localizes with its target mRNAs (e.g. GlyRα2) within dendrites of 
spinal cord motor neurons. Likewise, an earlier study reported a granular localization of 
Nova1 in the cytoplasm and in neurites of motoneurons in a manner overlapping with 
nELAV, another neuronal RBP (Ratti et al. 2008). The final model of Racca et al. 
suggests a combined function of Nova that comprises the regulation of alternative splicing 
in the nucleus and the regulation of mRNA expression in the cytoplasm (Racca et al. 
2010). In agreement with this hypothesis earlier studies already provided indirect 
evidence that Nova1 protein might have a regulatory function in the cytoplasm. For 
example, HITS-CLIP analysis of Nova proteins (Nova1 and Nova2) in mouse brain 
revealed interactions of Nova with 3′ untranslated regions of RNAs and further 
discovered that Nova regulates alternative polyadenylation of mRNAs in the brain 
(Licatalosi et al. 2008).  
In conclusion, the findings of my thesis together with previous studies strongly suggest 
that Nova1 acts as a regulator of post-transcriptional gene expression in the cytoplasm. 
4.3  Nova1 is required for miRNA function  
Nova1 was shown to associate with the 3’UTR of a huge number of mRNAs (Licatalosi 
et al. 2008) which led to the hypothesis that Nova1 regulation is not limited to miR-134 
but affects other miRNAs, as well. Another functionally important miRNA in the brain is 
miR-138. It mediates the translational repression of the depalmitoylation enzyme APT1 
and thereby regulates the size of dendritic spines (Siegel et al. 2009). 
Results from luciferase assays that were performed in the context of overexpressed as 
well as endogenously expressed miR-138 revealed that Nova1 is also required for the 
activity of miR-138 (Figure 8 and Figure 9). This suggests that Nova1 does not act 
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exclusively miR-134 - specific but might play a more general role in the regulation of 
miRNA activity. 
Further luciferase based experiments provided evidence that the observed effects of 
Nova1 knockdown on the miRNA-mediated mRNA repression were indeed dependent 
on the activity of miRNAs. By analyzing different miRNA targets (LIMK1, IQGAP1, 
LIN41 and HMGA2) in luciferase reporter assays using mutated miRNA binding sites, I 
found that Nova1 regulates most of the tested target mRNAs in a miRNA-dependent 
manner (Figure 10). One exception is the HMGA2 reporter that was shown to be regulated 
by Nova1 in a let-7-independent manner. This observation could be explained by the 
existence of other miRNA binding sites in the HMGA2 3’UTR that are regulated by 
Nova1. Since my data suggests Nova1 as a general miRNA regulator, other miRNAs 
targeting HMGA2 might cover a let-7-dependent effect. This theory is supported by the 
finding that most of the miRNA binding site mutations do not completely abolish the 
Nova1-mediated increase of the reporter expression. However, this data is also consistent 
with a miRNA-independent component in Nova1 regulated mRNA translation.  
With respect to the observation that Nova1 can act in a miRNA-dependent manner, it was 
important to test whether the availability of a miRNA binding site alone is sufficient for 
the regulatory function of Nova1. Results from a luciferase assay with a reporter lacking 
3’UTR sequences flanking miRNA binding sites revealed that the miRNA binding sites 
alone are sufficient to mediate the effect of Nova1 knockdown (Figure 11). This suggests 
that Nova1 can act as a regulator of miRNA activity independent of the 3’UTR sequence.  
4.4  Nova1 associates with miRISC and mRNA 
The miRNA-mediated translational repression of mRNA targets requires the association 
of AGO protein with a GW182 (Tnrc6) protein. The Ago-GW182 interaction forms the 
core of the miRISC, a multiprotein complex that is recruited by miRNAs to their 
respective target mRNAs (Fabian et al. 2012). The correct function of the miRISC is 
controlled by associated proteins that interact directly or indirectly with either the core 
miRISC or the target mRNA. For example, some of the miRISC interacting proteins 
belong to the family of DEAD-box RNA helicases like Ddx6 and Mov10, which interact 
with Ago proteins to facilitate miRNA-mediated translational repression (Chu et al. 2006; 
  DISCUSSION 
75 
 
Nicklas et al. 2015; Banerjee et al. 2009). Other modulators of miRNA activity, like Fmrp 
and Rbm4 directly or indirectly associate with AGO but also interact with AGO-
associated miRNAs and target mRNAs (Edbauer et al. 2010; Li et al. 2014; Lin et al. 
2009). Interestingly, Rbm4 and Smd1 are required for miRNA activity, independent of 
their essential function in mRNA processing (Xiong et al. 2015). Similarly, we envision 
that Nova1 might facilitate miRISC function in neurons independently of its originally 
described role in the regulation of alternative splicing.  
Since many of the miRISC modulating proteins are associating with Ago proteins, I 
hypothesized that Nova1 might regulate miRNA function via an interaction with Ago. I 
showed using co-Immunoprecipitation (co-IP) experiments with rat hippocampal lysates 
that Ago protein was precipitated with a pan-Ago antibody that can recognize all four 
Ago proteins. The successful pulldown was confirmed for Ago2 (Figure 13). Since a 
positive precipitation of Ago1, Ago3 and Ago4 was not tested, the assay only allows a 
conclusion about a potential interaction between Nova1 and Ago2 protein. Indeed, I 
observed a specific co-precipitation of Nova1 in the Ago-IP fraction which indicates that 
Nova1 interacts with Ago2 (Figure 13 A). Further co-IP experiments revealed that this 
interaction does not require the presence of RNA which suggests that Nova1 and Ago 
associate in a complex via protein-protein interaction (Figure 13 B).  
Despite the fact that Nova1 and Ago were successfully co-immunoprecipitated, some 
limitations of the co-IP experiment should be considered for future studies. First, due to 
the reported association of Ago with cellular membranes (Cikaluk et al. 1999; Stalder et 
al. 2013), Ago IP required harsh lysis conditions that in principle could impair a Nova1-
Ago interaction. This could explain the relatively small amounts of Nova1 that were 
detected in the Ago-IP. I further observed that in other cell systems, like cultured primary 
cortical neurons, the Nova1-Ago interaction was not preserved with the same buffer 
conditions. To overcome this problem in future experiments it might be helpful to use 
milder lysis conditions that preserve protein-protein interactions better. Regarding the 
interaction of Nova1 with Ago, another approach for future analysis could be an in vitro 
binding assay of Ago and Nova1 that includes Nova1 constructs with mutations in 
potential binding sites for Ago. Another limitation of the experiments was the inability to 
detect Ago proteins in Nova1-IPs. A possible reason could be that the Nova1 antibody 
masks the binding site for Ago which would perturb the Nova1-Ago interaction. 
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However, this interpretation is unlikely, since I used several different Nova1 antibodies, 
most of which efficiently worked in IP experiments (data not shown).  
All together my data argues for a relatively weak interaction of Nova1 with Ago but 
suggests that Nova1 regulates the expression of miRNA target mRNAs through an 
association with miRISC. Moreover, it is likely that additional protein binding partners 
of Nova1, like translation factors, might be required for its potential function in 
translational repression.  
A potential association of Nova1 with the miRISC was further supported by my analysis 
of interaction between Nova1 and miRNA target mRNAs. RNA-immunoprecipitation 
(RIP) experiments revealed that Nova1 specifically interacts with the endogenous miR-
134 target mRNA Limk1 (Figure 14). In principle, this result could support a model 
whereby Nova1 directly contacts miRNA target mRNAs, such as Limk1. However, this 
hypothesis is not in agreement with the results from the co-IP that showed an RNA-
independent interaction of Nova1 with miRISC. Therefore, it is more conceivable that 
Nova1 indirectly associates with mRNA via components of the miRISC (e.g. Ago), since 
the buffer conditions used of the RIP are expected to preserve protein-protein interactions.  
The Nova1 association with Limk1 mRNA is in accordance with the observation that 
Nova1 represses the expression of the Limk1-luc reporter in a miR-134-dependent 
manner (Figure 10 A). Moreover, results from Western Blot analysis of lysates from 
Nova1 depleted cells support the repressive function of Nova1 on Limk1 expression. 
Endogenous protein amount of Limk1 was significantly increased upon knockdown of 
Nova1 in hippocampal lysates (Figure 12). 
Furthermore, the artificial recruitment of Nova1 to the 3’UTR in the context of an mRNA 
tethering assay showed that Nova1 is able to induce translational repression independent 
of its RNA binding activity (Figure 15). Considering the fact that Nova1 can regulate 
miRNA activity independently of the 3’UTR context (Figure 11), we envision that Nova1 
might act towards miRISC activity in a more general way that does not necessarily 
involve specific RNA contact. This also suggests that Nova1 would regulate the 
translation of a vast majority of miRNA targets that are expressed in neurons. However, 
Nova1 might still have some target specificity due to the existence of different pools of 
miRISCs which either contain Nova1 or not. Putative determinants could be the miRNA 
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sequence, the complementarity of the miRNA at the binding site, the identity of the Ago 
protein or other associated unknown factors.  
Nova1 is well known for the ability to bind RNA by virtue of its three K-homology (KH) 
type domains (Buckanovich et al. 1997). These three KH domains are connected through 
small linker elements and span the major part of the protein sequence beside two motifs 
for nuclear localization and export. Although the amino acid structure of Nova1 does not 
contain motifs that are known to mediate protein-protein interactions, several Nova1 
interaction partners have been described in the literature.  
First, yeast-two hybrid identified the brain-enriched polypyrimidine tract-binding protein 
(brPTB) as a Nova interacting factor (Polydorides et al. 2000). Interestingly, brPTB is 
closely related to the polypyrimidine tract-binding protein (PTB) that was later implicated 
in the regulation of miRNA function (Engels et al. 2012; Xue et al. 2013). Furthermore, 
Nova1 shares sequence and functional similarities with the known miRISC associated 
factor FMRP (Jin et al. 2004b; Buckanovich et al. 1996). FMRP is associated with the 
miRNA processing machinery and interacts with Ago (Jin et al. 2004b; Edbauer et al. 
2010; Caudy et al. 2002). By comparing Nova1 and FMRP it is striking that both contain 
a KH1 and KH2 domain as well as NLS and NES motifs (Valverde et al. 2007). 
Furthermore, a crystallization study about binding properties of Nova1 KH1 and KH2 
domains reported that KH2 might be involved in protein-protein contacts (Teplova et al. 
2011). 
Results from tethering assays with two truncated variants of the Nova1 protein provided 
more insight into the parts of Nova1 that could facilitate its repressive activity. In contrast 
to the Nova1 full-length protein, none of the truncated proteins were able to repress the 
luciferase reporter significantly when being tethered to the reporter plasmid (Figure 16 
C). This suggests that a combination of domains present in both the N- and C-terminus 
of Nova1 is required for the repressive function of Nova1. Nevertheless, to uncover a 
specific domain or protein region that mediates this function, a more detailed domain 
mapping will have to be performed in future studies.  
To further reveal the mechanism that underlies Nova1 function in miRNA activity, it is 
important to investigate new direct binding partners of Nova1. A recent study used yeast 
two hybrid screens of mouse cDNA libraries with full-length Nova bait constructs in order 
to identify Nova-interacting proteins (Polydorides et al. 2000). However, this approach 
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does not provide the neuronal context that might be required for the Nova1 repressive 
function. This could be achieved for example by immunoprecipitation of Nova1 in lysates 
of neuronal origin followed by mass spectrometry to identify co-precipitated proteins. 
4.5  The significance of Nova1 for neuronal morphogenesis and 
function 
The functional relevance of miR-134 mediated mRNA inhibition includes the regulation 
of spine morphology and dendritic outgrowth. In particular, dendritic spine size is 
regulated by miR-134 through the repression of Limk1 mRNA (Schratt et al. 2006). 
Limk1 promotes actin polymerization and spine growth by phosphorylating ADF/cofilin 
proteins (Bamburg. 1999). The inhibition of Limk1 by miR-134 in turn promotes spine 
shrinkage. I found that Nova1 is necessary for the miR-134-mediated repression of the 
Limk1-luc reporter and additionally interacts with the Limk1 mRNA (Figure 10, Figure 
14). Importantly, I could further show that Nova1 deficiency, although not altering spine 
development on its own, specifically interfered with the miR-134-induced shrinkage of 
spines (Figure 17). In conclusion, this suggests that Nova1 does play a role in neuronal 
function, specifically in the miR-134-mediated spine size reduction. However, 
considering that Nova1 was also shown to be required for the activity of other neuronal 
miRNAs like miR-138 and miR-124, it is tempting to speculate that Nova1 function might 
be also relevant in the context of other miRNAs with reported neuronal functions. For 
example, overexpression of miR-138 induces shrinkage of spine volume, similar to miR-
134 (Siegel et al. 2009). Therefore, one approach for future studies would be to investi-
gate whether Nova1 is required for the miR-138 mediated spine size reduction by 
analyzing spine morphology upon Nova1 knockdown in the context of miR-138 
overexpression. 
BDNF is a neurotrophin that is synthesized and released upon stimulation of neuronal 
activity. It was shown that BDNF can release the inhibitory effect of miR-134 on Limk1 
mRNA translation (Schratt et al. 2006). However, the molecular mechanisms that are 
responsible for the BDNF-dependent inhibition of miRNA repressive activity are 
unknown.  
Since I found that the neuron-specific Nova1 protein is associated with miRISC, I further 
tested an involvement of Nova1 in the BDNF-mediated regulation of miR-134 activity. 
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First, results from luciferase assays showed that the treatment of BDNF induces a 
significant upregulation of the Limk1-luc reporter expression (Figure 19 A). This 
supports the previous findings reported in Schratt et al. (2006) that demonstrated a 
significant induction of translation of a Limk1-3’UTR luciferase reporter upon BDNF 
treatment. Moreover, results from luciferase assays revealed that under Nova1 
knockdown the BDNF-mediated increase of Limk1-luc expression was impaired (Figure 
19 A). This suggests that Nova1 might be involved in the dynamic control of Limk1 
mRNA translation in the response to BDNF stimulation. However, the molecular 
mechanism underlying this regulatory function still remains unclear. One possible 
explanation would be a BDNF-dependent downregulation of Nova1 expression. 
However, I could not obtain experimental support for this hypothesis in my thesis. Results 
from Western blot analysis of lysates from BDNF-treated cortical neurons did not detect 
any changes in the total amount of Nova1 protein compared to untreated cells. (Figure 19 
B). Therefore, BDNF might not affect total protein amounts of Nova1 but could control 
its subcellular localization and/or repressive activity by inducing specific post-
translational modifications. Interestingly, Nova1 was shown to harbor serine and 
threonine rich domains that serve as potential phosphorylation sites. A serine residue 
located in exon E4 was identified as a major phosphorylation site (Dredge et al. 2005). 
However, its functional relevance is still unclear. It is conceivable that BDNF could lead 
to alterations in the phosphorylation state of Nova1, thereby modulating its repressive 
function in the context of miRNA-dependent Limk1 mRNA translation. 
To test these hypotheses in the future, a more detailed analysis of the Nova1 subcellular 
localization in neurons is required, e.g. by performing Nova1 Western blot with nuclear 
and cytoplasmic fractions of BDNF treated neurons. Another approach would be to ana-
lyze the phosphorylation state of Nova1 upon BDNF stimulation with a phospho-specific 
Nova1 antibody, which would require the previous identification of the exact 
phosphorylation site, e.g. using mass spectrometry. 
It is tempting to speculate that Nova1 function is specifically required for dynamic 
activity-dependent changes in neuronal morphology, such as those occurring in synaptic 
plasticity. In this regard, it would be interesting to investigate whether the interaction 
between Ago and Nova1 is modified by synaptic stimuli or related growth factors (e.g. 
BDNF).  
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MiR-134 is not only involved in spine morphology but also essential for the activity-
dependent regulation of dendritogenesis. This effect is mediated by miR-134-dependent 
inhibition of the translational repressor Pumilio2 (Pum2). Previous work demonstrated 
that upon stimulation of hippocampal neurons with KCL or BDNF the dendrite outgrowth 
was increased in number of branches and total length (Fiore et al. 2009). 
In order to test whether Nova1 is involved in the regulation of dendritogenesis, I initially 
investigated the dendritic complexity upon Nova1 knockdown in non-stimulated neurons. 
The results revealed that Nova1 does not seem to have a major functional relevance in 
the regulation of dendritic outgrowth under basal conditions (Figure 18 B). An 
explanation for this observation could be that Nova1 depletion perturbs the activity of 
most miRNAs (see above). Since neuronal miRNAs were shown to have both inhibitory 
and stimulatory activity in dendritogenesis, the net effect would be expected to be small.  
We found, that dendritogenesis in neurons lacking the essential miRNA biogenesis 
component Drosha was similarly unaltered. The resulting loss of the majority of miRNAs 
did not cause any significant changes in dendritic outgrowth presumably due to a balance 
of opposing effects in dendritogenesis (Störchel and Thümmler et al. 2015). 
Although Nova1 knockdown did not affect overall dendritic complexity, it caused a slight 
but specific reduction in the growth of distal dendrites (Figure 18 A). This suggests an 
involvement of Nova1 in the local regulation of distal dendrites. It was shown that den-
dritic compartmentalization is, among others, modulated by AMPAR-type glutamate 
receptors (AMPAR) whose density increases with increasing distance from the cell soma. 
AMPAR function and trafficking into synaptic membranes is mediated by specific 
regulatory proteins (TARPs, transmembrane AMPA receptor regulatory proteins) that 
were for example shown to promote dendritic growth in either proximal or distal zones 
of dendrites in pyramidal neurons depending on the age of the cells (Hamad et al. 2014). 
It was further reported that a higher number of AMPA-receptors in the distal dendritic 
zones is accompanied by higher synaptic transmission. Synaptic properties that are 
determined by their position in the dendritic tree are known as distance-dependent scaling. 
This phenomenon is necessary for balancing the weakening of action potential currents 
that are filtered while traveling along the dendrite (Ito et al. 2009; Shipman et al. 2013). 
One possible approach to test whether Nova1 is involved in dendrite 
compartmentalization would be to investigate the expression or function of AMPAR 
regulating proteins, such as TARPs, in Nova1-deficient hippocampal neurons. 
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On the other hand, considering my observation that Nova1 was interfering with the 
BDNF-induced upregulation of the Limk1-luc reporter expression, it might be possible 
that Nova1 has a more prominent role in activity-dependent dendritogenesis. Future 
analysis of Nova1 deficiency in dendritic complexity upon neuronal stimulation with 
BDNF or other activity-related stimuli could yield more information about a putative 
involvement of Nova1 in this context. 
4.6  Conclusion and Outlook 
The main aim of this project was to obtain more insight into the molecular mechanism by 
which miRISC activity is regulated in neurons. Based on a previous large-scale RNAi-
based screening study, the RBP Nova1 was identified and further characterized as a new 
miRISC activator in primary neurons. Originally described as an essential regulator of 
alternative splicing in the nucleus, Nova1 might therefore also function as post-transcrip-
tional regulatory RBP in the cytoplasm. My findings therefore provide further evidence 
that RBPs dynamically participate in the post-transcriptional control of gene expression 
in different cellular compartments.  
The main findings related to Nova1 function gathered during this thesis can be 
summarized in a simple working model (Figure 20). Under basal conditions Nova1 
shuttles to the cytoplasm where it can associate with miRISC potentially via a direct 
protein interaction with Ago proteins. However, which of the 4 mammalian Ago proteins 
are direct binding partners of Nova1 remains to be investigated. The Nova1-Ago 
interaction serves to place the Nova1 repressive activity to the translation machinery. 
How Nova1 interferes with mRNA translation, and whether this is strictly Ago-dependent 
is still unclear. Therefore, it is very important to elucidate additional Nova1 interacting 
proteins, e.g. factors associated with translational regulatory complexes, in future studies. 
Furthermore, Nova1 probably participates in the BDNF-dependent release of miRNA 
repressive activity, a mechanism which is still highly elusive. How Nova1 function is 
modulated by BDNF remains an important subject for future experiments.   
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Figure 20: Model of Nova1 function in the regulation of miRNA activity 
Nova1 can associate with miRISC in the cytoplasm via a direct protein interaction with Ago. Nova1 
promotes translational repression of the Ago loaded miRNA target mRNAs. The Ago-Nova1 interaction 
might be modified upon BDNF release and thereby contributes to dynamic activity-dependent regulation 
of miRNA activity. 
The loss of Nova1 function as a regulator of miRNA activity in neurons might impair the 
proper regulation of activity driven processes that control synaptic strength and plasticity. 
This could have pathophysiological consequences for the human nervous system like for 
example in schizophrenia and epilepsy. These diseases were reported to be associated 
with alterations in specific miRNAs, including miR-134, mir-138 and miR-124 (Jimenez-
Mateos et al. 2012; Santarelli et al. 2011; Kan et al. 2012; Beveridge et al. 2010; Peng et 
al. 2013). Since Nova1 is part of miRISC in neurons, it is likely that loss of function 
mutations in the Nova1 gene might cause dysregulation of other neuronal miRNAs that 
are associated with different kinds of neurological disorders. Interestingly, several 
publications link Nova1 to the pathogenesis of certain neuropsychiatric diseases. For 
example, NOVA1 was identified in a genome-wide study as promising candidate gene 
for a genetic predisposition for antipsychotic-induced parkinsonism, a developed side 
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effect of neuroleptic schizophrenia medication (Alkelai et al. 2009). Other studies showed 
changes in the subcellular distribution of Nova proteins in cortical and hippocampal 
neurons of mouse brain as well as altered Nova1 mRNA expression in the striatum of rats 
in response to induced epileptic seizures (Eom et al. 2013; Jelen et al. 2010). Furthermore, 
Eom and colleagues propose a Nova-dependent regulation of mRNAs that are associated 
with epilepsy. Recently, Rusconi and colleagues observed a downregulation of Nova1 in 
mouse hippocampal neurons in response to pilocarpine-induced status epilepticus 
(Rusconi et al. 2015). A later study uncovered several novel genes, including NOVA1, 
that are associated with major depressive disorder (MDD) (Malki et al. 2013). MDD is a 
neuropsychiatric disease that has also been linked to miRNA dysregulation in the recent 
years (Geaghan et al. 2015).  
In summary, in the presented project a neuron-specific RBP was uncovered in the context 
of miRNA activity regulation that represents a new modulating factor at the level of 
miRISC. This study should therefore contribute to a better understanding of the regulatory 
mechanism that are required for neuronal miRNAs to accomplish their versatile roles in 
neuronal development and plasticity.
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6.2  List of abbreviations 
Ago   Argonaute 
Apt1   Acyl-protein thioesterase 1 
BDNF   brain derived neurotrophic factor 
cAMP   cyclic adenosine monophosphate 
cDNA   complementary DNA 
co-IP   co-immunoprecipitation 
CRE   cAMP response element 
CREB   CRE-binding protein 
CTX   cortex 
Ddx6   DEAD-box helicase 6 
Dgcr8   DiGeorge syndrome critical region 8 
DHX36   DEAH-box helicase 36 
DIV   days in vitro 
DNA   deoxyribonucleic acid 
Dnd1   Dead end protein homolog 1 
E. coli   Escherichia coli 
Ewsr1   Ewing sarcoma breakpoint region 1 
FCS   fetal calf serum 
FMRP   Fragile X mental retardation protein 
Fubp1   Far upstream element binding protein 1 
FUDR   5-fluorodeoxyuridine 
GFP   green fluorescent protein 
GTP   guanosine triphosphate 
h  hour 
HC   hippocampus 
HDAC2   Histone deacetylase 2 
Hmga2   High mobility group AT-hook 2 
HuR   Human antigen R 
ICC   immunocytochemistry 
Iqgap1   IQ motif containing GTPase activating protein 1 
kb   kilobase 
KCL   potassium chloride 
 APPENDIX 
101 
 
kDa   kilodalton 
LB   Luria-Bertani 
Limk1   LIM domain kinase 1 
Lin41   Lineage variant 41 
Lsm7   Sm-like protein 7 
LTD   long-term depression 
LTP   long-term potentiation 
luc   luciferase 
MAP2   Microtubule-associated protein 2 
Mef2   Myocyte enhancer factor 2 
MEM   minimum essential medium 
miRISC   microRNA-induced silencing complex 
miRNA   microRNA 
MOV10   Moloney leukemia virus 10 
mRNA   messenger RNA 
mTOR   mechanistic target of rapamycin 
mut   mutant 
NB   Neurobasal medium 
Ncoa3   Nuclear receptor coactivator 3 
NMDA   N-Methyl-D-aspartate 
Nova1   Neuro-oncological ventral antigen 1 
Nxf1   Nuclear RNA export factor 1 
Nxt1   Nuclear transport factor 2 like export factor 1 
PABP   Poly(A)-binding protein 
PCR   polymerase chain reaction 
pre-miR   precursor microRNA 
pri-miRNA   primary microRNA 
PSD-95   Postsynaptic densitiy protein 95 
PUM1   Pumilio homolog 1 
rAAV   recombinant adeno-associated virus 
Rbm25   RNA binding motif protein 25 
Rbm4   RNA binding motif protein 4 
RLA   relative luciferase activity 
RNA   ribonucleic acid 
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RNAi   RNA interference 
RNA-IP   RNA-immunoprecipitation 
RNase   ribonuclease 
Rpl5   60S ribosomal protein L5 
RT-qPCR   Real Time-quantitative PCR 
sec seconds 
shRNA   small hairpin RNA 
siRNA   small interfering RNA 
Smd1   Small nuclear ribonucleoprotein D1 
Tnrc6c   Trinucleotide repeat-containing gene 6C 
TRBP   Trans-activating response RNA-binding protein 
TTX   tetrodotoxin 
U2af1   U2 small nuclear RNA auxiliary factor 1 
Ube3a1   Ubiquitin-protein ligase E3A 1 
V   Volt 
WT   wildtype 
XRN1   5’-3’-exonuclease 1 
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